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The conditions defining whether microglial activation is detrimental
or beneficial to neuronal survival are still poorly understood. Better
understanding of the factors regulating microglia activation may lead to
improved therapies for neurodegenerative diseases. Clinical and animal
studies point to the neuroprotective and anti-inflammatory effects of steroid
hormones. However, our comprehension of the cellular targets and
mechanisms of action of these hormones in the CNS is still unresolved. In
view of these limitations, the main question addressed in this dissertation
was the role that microglia play in the anti-inflammatory effects of steroid
hormones in the brain, with particular emphasis on the neuroprotective
hormone 17β -estradiol (E2), and the anti-inflammatory steroid,
corticosterone.
To address this problem, microglia culture models were established
using a microglia cell line and primary cultures from transgenic mice that
facilitate the identification of microglia by EGFP expression. Collaborative
studies were also done in mice in vivo. The expression of steroid hormone
receptors was studied as well as their function. This dissertation shows that
microglia cells are not direct targets of estrogen actions, but respond
profoundly to glucocorticoids, which exert anti-inflammatory effects on the
production of cytokines like TNFα, IL-6 and NO. Steroid hormones can be
produced within the brain. In this dissertation, microglia cells are shown to
participate in the metabolism of steroids through expression of steroid-
converting enzymes. Expression of 11βHSD1 in microglia mediated an
autocrine re-activation of glucocorticoids, whereas, expression of enzymes
like 17βHSD1 and 5αR catalyzed the conversion of active androgens and
estrogens from steroid hormone precursors AD and DHEA. These
microglia-derived hormones had estrogenic effects on neuronal cells, as
described in the last section of this dissertation where the characterization
and responsiveness of a neural progenitor cell line are presented.
In summary, microglia cells are highly susceptible to the action of
glucocorticoids, but not estrogens. This specificity is dictated by the
abundant expression of glucocorticoid receptors, and a minimal expression
of estrogen receptors. A novel role of microglia is also presented. Microglia
express steroid-metabolizing enzymes, which mediate the autocrine re-
activation of glucocorticoids, or the production of active androgens and
estrogens from steroid hormone precursors.
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Microglia cells are the resident Central Nervous System macrophages
Early anatomical and cytological studies done by del Rio-Ortega (del
Rio-Ortega, 1932) revealed a unique cell type differing in morphology from
neurons and supporting glial cells designated as microglia (Fig.1A). These
cells, which constitute approximately 12% of the brain, are distinguished by
their small cell body and highly ramified morphology (Fig.1A-B). Microglia
cells populate the brain early in development as bone marrow-derived
monocytes with phagocytic functions, and eventually differentiate into
resident parenchymal brain cells during the postnatal period [rev. by
(Lawson, Perry et al. 1990)]. In the adult, two populations of microglia have
been described: a slow turnover, resident population of cells within the brain
parenchyma, and a high turnover population of cells that are found in the
meninges, choroids plexus, walls of the ventricles, and other structures
devoid of the blood brain barrier (Lawson, Perry et al. 1992).
Microglia are present in large numbers in all major regions of the
brain but are not uniformly distributed (Lawson, Perry et al. 1990). The
majority of microglia are found in gray matter (vs white matter); densely
2
3
populated areas include the hippocampus, olfactory telencephalon, basal
ganglia and substantia nigra, while less densely populated areas include fiber
tracts, cerebellum and much of the brainstem. The cerebral cortex, thalamus
and hypothalamus have intermediate cell densities relative to those discussed
(Lawson, Perry et al. 1990). In the normal/resting (steady state) adult
nervous system very little is known about the functions of microglia. Yet,
emerging evidence indicates microglia actively scan their environment for
any disturbances (Davalos, Grutzendler et al. 2005; Raivich 2005). Being the
resident brain macrophages, microglia have important immunological and
pathological functions (Aloisi 2001; Block and Hong 2005). As effector
cells they are able to directly kill microorganisms and tumor cells, and they
also partake in tissue remodeling processes controlling synaptogenesis and
neuronal death (Marin-Teva, Dusart et al. 2004; Bessis, Bechade et al.
2007). However, microglia are best characterized for their involvement in
brain inflammation.
Inflammation and Neurodegeneration
The inflammatory response is designed to activate local resident
macrophages and attract circulating immune cells to the site of damage or
infection, for the clearance of tissue debris or initiation of adaptive immune
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responses, respectively. Microglia become rapidly activated in response to
brain injury or immunological stimuli (Kreutzberg 1996; Raivich,
Bohatschek et al. 1999). Activated microglia show characteristic
morphological changes that include the shortening of processes and a
hypertrophied cell body. Additionally, activated microglia release a number
of soluble factors, like cytokines, which are pro-inflammatory in nature [rev.
by (Raivich, Jones et al. 1999; Block and Hong 2005)]. These molecules
activate surrounding microglia and astrocytes, change the permeability of
endothelial cells, and induce the infiltration of blood leukocytes and
lymphocytes to the inflamed tissue [rev. (Raivich, Bohatschek et al. 1999)].
Localized inflammatory responses are normally resolved by the late
expression of anti-inflammatory cytokines and other tissue factors [rev.
(Raivich, Bohatschek et al. 1999)], which in turn, resolve the production of
inflammatory molecules and induce the clearance of activated cells.
Inflammation is a normal physiologic response, but without appropriate
regulation it causes damage to the otherwise, healthy tissue. This is
particularly true in the central nervous system (CNS) due to the high
metabolic state of neurons and their susceptibility to environmental changes.
An unregulated response by microglia leads to elevated and sustained
levels of inflammatory mediators such as superoxide, nitric oxide and TNFα
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(Colton and Gilbert 1987; Sawada, Kondo et al. 1989; Liu, Gao et al. 2002),
which become highly neurotoxic (Block and Hong 2005). As demonstrated
by the doubling of research articles about microglia during the last 6 years
(119 titles in 2000 vs 226 in 2006 (NCBI, Pub Med)), an increased interest
in the role microglia play in the initiation and maintenance of inflammation
in the brain is evident. Increasingly, chronic or un-regulated inflammation is
being recognized as a main contributing factor to the progression and
etiology of neurodegeneration (Giovannini, Scali et al. 2003; Morale, Serra
et al. 2006; Bonifati and Kishore 2007), as well as other body diseases like
arthrosclerosis (Chait, Han et al. 2005), arthritis (Mizuno 2006),
osteoporosis (Clowes, Riggs et al. 2005; Ginaldi, Di Benedetto et al. 2005).
Inflammation and steroid hormones
Systemic inflammation increases cytokine levels in the blood stream,
and causes activation of a major neuro-endocrine circuit known as the
hypothalamic-pituitary-adrenal (HPA) axis (Turnbull and Rivier 1995;
Buckingham, Loxley et al. 1996; Beishuizen and Thijs 2003). HPA axis
activation leads to the rapid production of adrenal steroids (glucocorticoids)
and their release into circulation. Glucocorticoids are potent endogenous
anti-inflammatory molecules (Dannenberg 1979; Umland, Schleimer et al.
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2002), which affect cells involved in the inflammatory response by
interfering with the activation of early inflammatory transcription factors
like the p65 NFkB subunit as well as AP-1 (Smith, Burke et al. 1996;
Sakurai, Shigemori et al. 1997; De Bosscher, Vanden Berghe et al. 2000;
Gonzalez, Jimenez et al. 2000). Glucocorticoids also alter the distribution
and trafficking, as well as the differentiation and maturation, of
macrophages/monocytes and other blood leukocytes (Sorrells and Sapolsky
2007).
However, glucocorticoids can also act as immune-enhancing agents
(Yeager, Guyre et al. 2004). For instance, moderate levels of corticosterone,
induced by acute stress or administered directly, enhance skin immune
reactions by increasing leukocyte trafficking, while chronic or high doses are
inhibitory (Dhabhar and McEwen 1999). Thus, it becomes important to view
steroid hormones not solely as immunosuppressant, but rather as modulators
of inflammation.
This regulatory role has also been evident in a different class of
steroid hormones, the sex hormones, where clinical and animal studies of
inflammatory diseases have shown that they too can modulate inflammation
(Whitacre, Reingold et al. 1999; Behl 2002; Wagner, Kaplan et al. 2002).
One of the most widely studied steroids in this area has been the female sex
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hormone 17β-estradiol (E2) (Cutolo, Sulli et al. 1995; Roof and Hall 2000;
Garcia-Segura, Azcoitia et al. 2001; Rogers and Eastell 2001; Behl 2002;
Hodgin and Maeda 2002; Pfeilschifter, Koditz et al. 2002; McCullough and
Hurn 2003; Wise, Dubal et al. 2005).
Sex hormone status dictates severity and progression of inflammatory
disease
Women generally present a more robust immune response than men:
for example, they have more potent antigen presenting cells, higher
circulating immunoglobulin levels, and stronger antigen specific humoral
immune responses. In fact, females have 10 times higher propensity to
develop autoimmune disorders compared to men  [rev. by (Mor, Nilsen et al.
1999)]. E2 has been demonstrated as one of the sex hormones that influences
the progression of different inflammatory pathologies such as cardiovascular
disease, (Hodgin and Maeda 2002; Wagner, Kaplan et al. 2002),
osteoporosis  (Turner, Riggs et al. 1994; Watts 2002), and autoimmunity
(Cutolo, Sulli et al. 1995).
While in the periphery E2 usually is pro-inflammatory, in the CNS it
is considered as an anti-inflammatory hormone. Evidence from clinical trials
and animal studies suggests that E2 is associated with a decreased incidence,
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delayed onset and delayed progression of acute and chronic brain disorders,
ranging from stroke and schizophrenia to Alzheimer’s disease, multiple
sclerosis, and Parkinson’s disease (Chowen, Azcoitia et al. 2000; Roof and
Hall 2000; Lee and McEwen 2001; Behl 2002; Bisagno, Bowman et al.
2003). The reduced susceptibility to acute brain injury, such as cerebral
ischemia, neurotrauma and certain neurotoxic agents, in pre-menopausal
females, both in humans and rodents, strongly suggests a correlation
between the levels of E2 and the severity and progression of inflammatory
diseases.
Steroid hormones affect brain injury and repair
Sex steroids have multiple effects in the CNS. Aside from
reproduction, perhaps the most important role for these hormones is
neuroprotection (McEwen 2001; Behl 2002). Estrogens, progesterone (P),
and androgens, have potent neuroprotective actions (Wise, Dubal et al. 2001;
Stein and Hoffman 2003; Schumacher, Guennoun et al. 2004; Hoffman,
Merchenthaler et al. 2006; Singh 2006; Singh, Dykens et al. 2006). Animal
studies show that these hormones protect against several types of injury,
such as brain trauma, and enhance recovery after stroke and spinal cord
injury (Kalimi, Shafagoj et al. 1994; Cardounel, Regelson et al. 1999; Stein
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2001). In comparison to E2, the neuroprotective effects of androgens such as
testosterone (T) are not as clear, although T deficiency has been associated
with increased symptoms of Parkinson’s Disease (Okun, McDonald et al.
2002; Okun, Walter et al. 2002).
The protective effects of E2 and other sex steroids on neurons have
been extensively demonstrated in CNS damage models such as ischemia,
glutamate excitotoxicity, oxidative stress, amyloid-β toxicity, and neuronal
apoptosis (Wang, Santizo et al. 1999; Belcredito, Vegeto et al. 2001; Garcia-
Segura, Azcoitia et al. 2001; Stein 2001; Behl 2002; Cordey, Gundimeda et
al. 2003; McCullough and Hurn 2003; Rau, Dubal et al. 2003; Rau, Dubal et
al. 2003; Sawada and Shimohama 2003; Guerra, Diaz et al. 2004; Wen,
Yang et al. 2004; Corasaniti, Amantea et al. 2005; Heyer, Hasselblatt et al.
2005; Platania, Seminara et al. 2005; Wu, Wang et al. 2005; Morale, Serra et
al. 2006). However, the mechanisms by which sex hormones affect CNS
inflammation and cytokine production are less well understood.  To address
this issue, several studies have focused on microglia and astrocytes, given
that these cells are pivotal in orchestrating the inflammatory response in the
CNS (Mor, Nilsen et al. 1999; Raivich, Bohatschek et al. 1999; Raivich,
Jones et al. 1999; Jankowsky and Patterson 2001; Hagberg and Mallard
2005; Ladeby, Wirenfeldt et al. 2005; Panickar and Norenberg 2005).
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Evidence to date suggests microglia, like peripheral macrophages, are targets
of direct steroid action through the expression of sex hormone receptors.
Multiple studies in mammalian species (rodents, and lower primates)
document the expression of estrogen receptors (ERα, ERβ) and androgen
receptors (AR) in glial cells (astrocytes and oligodendrocytes) (Gahr,
Metzdorf et al. 1996; Finley and Kritzer 1999; Behl 2002). However reports
describing expression of such receptors in microglia, in vivo, are scarce
(Garcia-Ovejero, Veiga et al. 2002). It has also been shown that glial cells
become increasingly responsive to the actions of these steroids in the injured
CNS, as ERs and ARs are up-regulated after injury (Gahr, Metzdorf et al.
1996; Cooke, Hegstrom et al. 1998; Kruijver, Fernandez-Guasti et al. 2001;
Garcia-Ovejero, Veiga et al. 2002). In the normal rat brain, astrocytes
express low levels of ER and AR, which are transiently up-regulated in
astrocytes following excitotoxic/chemical injury to the hippocampus, or stab
wound to the parietal cortex and hippocampus (Garcia-Ovejero, Veiga et al.
2002). Under these circumstances AR is also induced in microglia (Garcia-
Ovejero, Veiga et al. 2002). Likewise, progesterone receptor (PR)
expression is up-regulated in neurons and glia, after CNS injury in the rat
(Bulloch 2001; Meffre, Delespierre et al. 2005).
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In the mouse CNS, E2 treatment decreases the recruitment of total
inflammatory cells as well as TNFα positive macrophages and T cells at the
onset of experimentally -induced auto-immune encephalitis (Ito, Buenafe et
al. 2002). However, in this study microglia only show a moderate
attenuation of the peak TNFα expression in response to E2 (Ito, Buenafe et
al. 2002). Recently, a comprehensive review of steroid receptor expression
in glial cells has been done by Garcia-Ovejero et al. (Garcia-Ovejero,
Azcoitia et al. 2005), indicating that in vivo, microglia are limited in the
expression of steroid receptors. These studies would suggest that E2 effects
on neuroinflammation may be mediated through other cells expressing
estrogen receptors.
Cytokine regulation by E2 and other hormones
In spite of the lack of evidence demonstrating estrogen receptor
expression in microglia in vivo, E2 is reported to block a number of
inflammatory mediators produced by activated microglia in vitro.
Specifically, E2 pre-treatment of activated microglia in response to
lipopolysaccharide (LPS), phorbol ester, or interferon-γ (IFNγ) stimulation
has been noted in the literature to attenuate phagocytic activity, inducible
nitric oxide synthase and matrix metalloproteinase-9 expression, as well as
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production of superoxide, nitric oxide (NO), and prostaglandin-E2 (Bruce-
Keller, Keeling et al. 2000; Drew and Chavis 2000; Vegeto, Bonincontro et
al. 2001). Additionally, in an in vitro HIV inflammatory model, viral
activation of microglia results in super oxide and NO production, increased
phagocytosis, and tumor necrosis factor-α (TNFα) release. HIV microglial
activation is suppressed by E2 pre-treatment through interference of viral-
mediated MAPK activation (Bruce-Keller, Barger et al. 2001). Other reports
indicate cytokines and surface receptors critical for adaptive immunity such
as IL-10, TNFα, IFNγ, MHC Class I, CD40, and CD86, are also regulated
by E2 in the microglia cell line, N9 (Dimayuga, Reed et al. 2005).
In contrast to the aforementioned studies, other studies have failed to
demonstrate anti-inflammatory actions of E2 on microglia/macrophages
(Dovio, Sartori et al. 2001; Suuronen, Nuutinen et al. 2005; Sierra in
preparation). Additionally, studies on microglia activation have found no
effects of E2, compared to other steroids such as glucocorticoids (Lieb,
Engels et al. 2003; Fowler, Johnson et al. 2005). Suuronen et al. (2005)
report anti-inflammatory effects of various selective estrogen receptor
modulators (SERMs), but not of E2, and further suggest that SERM-induced
modulation of LPS-activated pro-inflammatory signaling cascades is not
estrogen receptor-mediated (Suuronen, Nuutinen et al. 2005).
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In spite of the these apparently conflicting reports, several studies
support a pure anti-inflammatory role of E2 on microglia (Mor, Nilsen et al.
1999; Bruce-Keller, Keeling et al. 2000; Vegeto, Bonincontro et al. 2001;
Vegeto, Belcredito et al. 2003; Baker, Brautigam et al. 2004; Dimayuga,
Reed et al. 2005; Ghisletti, Meda et al. 2005; Liu, Liu et al. 2005; Vegeto,
Belcredito et al. 2006). Another set of studies with β-amyloid induction of
NO in microglia, show E2 acts in a biphasic fashion, dependent on dose and
milieu, in which high doses of E2 are inhibitory (Bruce-Keller, Keeling et al.
2000), and physiological doses of E2 stimulate NO secretion and toxicity
(Harris-White, Chu et al. 2001). In fact, recent papers have shown ovary-
derived E2 is essential for mounting a proper inflammatory response to
bacterial lipopolysaccharides (LPS), suggesting that circulating E2 is
exerting a permissive, pro-inflammatory effect (Soucy, Boivin et al. 2005).
The dichotomous effects of E2 on inflammation have been associated
with the failure of clinical trials to prove the benefits of hormone
replacement therapies (Stork, van der Schouw et al. 2004; Bushnell 2005;
Wise, Dubal et al. 2005). A proposed compounding factor in these clinical
trials could be responsiveness to E2, as Suzuki et al (2007) have suggested
in a model of postmenopausal ischemic stroke. Here the neuroprotective and
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anti-inflammatory actions of E2 were dependent on the extent of the hypo-
estrogenic period (Suzuki, Brown et al. 2007).
Given the aforementioned studies, it is quite clear that there is
controversy about the effects of estrogen on microglia activity. The view
that sex hormones, like E2, are universally anti-inflammatory agents needs
to be reconsidered given the lack of coherence in the literature. Steroid
hormones could be described more accurately as conditional immuno-
modulatory agents, exerting permissive, stimulatory, or inhibitory effects
depending on hormone concentration, endpoints measured, cell types
studied, and inflammation models used (Sternberg 2001; Dinkel, Ogle et al.
2002; Yeager, Guyre et al. 2004).
Sources of Steroid Hormones
The gonads and the adrenal glands are the principal sources of steroid
hormone synthesis in the body. Steroid hormones are derived from the
metabolism of cholesterol [rev. by (Pikuleva 2006)]. The first required step
for steroidogenesis is the transfer of cholesterol into the mitochondria
(Miller 1995), which is mediated by the steroid acute regulatory protein
(StAR) and the peripheral benzodiazepine receptor (PBR) (Hauet, Liu et al.
2002). Within the mitochondrial lumen, cholesterol is converted by the p450
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cytochrome side-chain cleavage (p450scc) into pregenenolone, which is
further metabolized in the cell’s endo-reticular system into progesterone,
dehydroepiandrosterone (DHEA) and androstenedione (AD) by the p450c17
and the 3β-hydroxysteroid dehydrogenase (HSD) enzymes [rev by (Simard,
Ricketts et al. 2005)]. The p450c21 enzyme can convert pregenenolone and
progesterone into the precursors for glucocorticoids and mineralocorticoids,
respectively (Simard, Ricketts et al. 2005). DHEA and AD are the
precursors for the androgens and estrogens, which are synthesized by
various enzymes, principally, 17βHSD, 3βHSD, p450-Aromatase
(p450Arom), and 5α-reductase. The steroidogenic pathway and the enzymes
mentioned are summarized in Figure 2.
Belief of the exclusive synthesis of steroid hormones in the gonads
and adrenals was held for a long time. It was thought that hormones secreted
into the circulation would then enter target tissues to exert their functions
[rev. by (McEwen, Biegon et al. 1982)]. Currently, however, it is recognized
that steroid synthesis/metabolism occurs in a number of tissues and cells,
such as adipose tissue (Feher, Bodrogi et al. 1982), liver (Katagiri, Tatsuta et
al. 1998), skin (Labrie, Luu-The et al. 2000), lungs (Kao, Crosswell et al.
1979), and notably, the brain (Tsutsui, Ukena et al. 1999; Baulieu, Robel et
al. 2001; Stoffel-Wagner 2003). Steroidogenesis (the conversion of
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cholesterol into pregenenolone and downstream steroids) is more limited,
but steroid conversion and metabolism appears to be much more widespread
than previously believed.
End-organ regulation of steroid hormone action
Humans and certain primates secret into circulation large amounts of
the steroid precursors DHEA and DHEA-sulfate (DHEA-S) from the
adrenals. These steroids do not bind any receptors, yet exert estrogenic and
androgenic actions after being converted into active estrogens and androgens
in target tissues (Labrie 1991; Labrie, Luu-The et al. 2001). In fact, in post-
menopausal women almost all sex steroids are produced from adrenal
precursors, and in adult men, approximately half of androgens are made
locally in target tissues (Labrie 2003; Labrie 2004).
Pathological conditions, such as breast cancer and chronic joint
inflammation, have provided some of the best-studied cases of intracrine
steroid synthesis/conversion, where local steroid production plays an active
role in disease. Breast cancer cells can locally synthesize or regenerate
estrogens, which serve as growth factors promoting tumor growth and
persistence [rev by (Labrie 2003; Salhab, Reed et al. 2006)]. Therefore,
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development of inhibitors for steroid-converting enzymes has become an
active area of research (Purohit, Woo et al. 2001). In chronic inflammatory
disease, such as osteoarthritis and rheumatoid arthritis, tissue synovial cells
display increased production of estrogens with pro-inflammatory effects
(Schmidt, Weidler et al. 2005). This pro-estrogen pathway can be blocked
by the androgens, AD and T, which are converted into 5α-hydroxylated
androgens that have anti-inflammatory properties (Schmidt, Weidler et al.
2005).  In cases such as this, appreciation of the steroid-converting
properties in the inflamed tissue can aid in the choice of therapeutic steroids
to be used (Labrie 2003).
Not all intracrine steroid metabolism leads to pathological conditions.
Local steroid synthesis can also contribute to the maintenance of
homeostasis in tissues. Such is the case with the brain, as indicated by
various reports on brain development (Tsutsui 2006), neurotransmission
(Majewska 1992; Paul and Purdy 1992; Schumacher, Guennoun et al. 1997),
and recovery from damage (Azcoitia, Sierra et al. 2001; Azcoitia, Sierra et
al. 2003; Schumacher, Guennoun et al. 2004).
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Neurosteroidogenesis: synthesis of steroids in the brain
In the early 1980s, Corpechot et al. (1981) found a high concentration
of pregenenolone and DHEA in brains of adrenalectomized and castrated
rats. They further demonstrated that these steroids were not affected by
adrenocorticotropic hormone, or by suppression of circulating
glucocorticoids (Corpechot, Robel et al. 1981). Soon after, the p450 side
chain cleavage cytochrome (p450scc), which converts cholesterol into
pregenenolone, was identified in the brain opening the possibility of de novo
brain steroidogenesis (Schumacher, Guennoun et al. 2004). The term
neurosteroid was coined, referring to steroids that are synthesized from
cholesterol or another early precursor in the nervous system (Robel and
Baulieu 1995).
In the CNS, DHEA is synthesized from pregenenolone by astrocytes
and neurons. Astrocytes can further metabolize DHEA into sex hormones
(Zwain and Yen 1999). Brain DHEA levels are higher than those in
circulation, and have been negatively correlated with aging and
neurodegeneration (Weill-Engerer, David et al. 2002). Additionally, DHEA
has multiple effects when administered to the CNS, including modulating
the activity of GABA and NMDA receptors [rev. by (Gibbs, Russek et al.
20
2006)], yet no specific receptor for this hormone has been detected
(Regelson and Kalimi 1994; Majewska 1995). This has led investigators to
suggest that in the brain DHEA may be metabolized into active steroid
hormones, which then mediate the observed effects of DHEA (Zwain and
Yen 1999; Schmidt, Kreutz et al. 2000; Jellinck, Lee et al. 2001; Jellinck,
Kaufmann et al. 2006; Jellinck Submitted). Evidence for this model has been
put forth by Veiga, et al. (2003) who have demonstrated that DHEA
mediated neuroprotection in a model of kainic acid toxicity is dependent on
the E2-synthesizing enzyme p450Arom (Veiga, Garcia-Segura et al. 2003).
Moreover, the principal cell types in the brain, including astrocytes, neurons,
and oligodendrocytes have been shown to convert DHEA into
androstenedione (AD), and produce downstream estrogens and androgens
(Zwain and Yen 1999). However, thus far, the participation of microglia in
the metabolism and conversion of steroids in the CNS has not been
addressed.
Neurosteroid levels correlate negatively with neurodegeneration
Neurosteroidogenesis has been described as an adaptive coping
mechanism following brain damage (Garcia-Ovejero, Azcoitia et al. 2005),
in agreement with the neuroprotective effects of DHEA (Mao and Barger
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1998; Lapchak, Chapman et al. 2000; Kaasik, Kalda et al. 2001; Lapchak
and Araujo 2001; Morfin and Starka 2001; D'Astous, Morissette et al. 2003;
Veiga, Garcia-Segura et al. 2003; Charalampopoulos, Alexaki et al. 2006;
Juhasz-Vedres, Rozsa et al. 2006; Wojtal, Trojnar et al. 2006) and estrogen
(Behl 2002). As androgens and estrogens can be pro- or anti-inflammatory
(Straub, Konecna et al. 1998; Jacobson and Ansari 2004; Cutolo, Capellino
et al. 2005), the steroid profile in a tissue may determine the extent of
inflammation (Schmidt, Naumann et al. 2006), and in the case of the brain,
of neurodegeneration. Neurodegeneration has been negatively correlated
with neurosteroid levels (Schumacher, Weill-Engerer et al. 2003).
Measurements of various neurosteroids in Alzheimer’s patients compared to
aged healthy controls showed a trend towards less steroids in the diseased
patients, as well as reduced DHEA metabolites; and a negative correlation
was established between Alzheimer’s biomarker proteins phospho-Tau and
β-amyloid, and these neurosteroid levels (Weill-Engerer, David et al. 2002).
These studies are highly suggestive of the neuroprotective role of steroids
that are synthesized or metabolized within the brain.
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Summary
Microglia cells are the resident brain macrophages, whose role in the
initiation and maintenance of brain inflammation has been firmly
established. Chronic or exacerbated inflammation can be deleterious to
resident cells, particularly in the nervous system. The most common
neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, multiple
Sclerosis, stroke induced neurodegeneration, etc., all share important
inflammatory components, which have become a current therapeutic target.
Steroid hormones are potent regulators of inflammation, particularly the
glucocorticoids and sex hormones. Additionally, sex hormones, such as E2,
have important neuroprotective effects. Neuroprotection afforded by E2 has
been linked to the anti-inflammatory properties of this hormone, yet as
previously stated, whether E2 directly affects microglia activation in vivo
remains unclear.
For the initial stage of my thesis work I set out to test the hypothesis
that estrogen exerts anti-inflammatory effects by acting directly on
microglia. To this end, I developed a cell culture system using a microglia
cell line, BV2, and primary microglia cultures from a transgenic mouse line.
I then tested and compared the steroid hormones, estrogen and
corticosterone, for their ability to modulate the activation of microglia with
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LPS, and found that corticosterone is a potent inhibitor of pro-inflammatory
cytokine production, while estrogen has no effects on microglia activation.
My results were consistent with further studies done in the laboratory
showing that microglia predominantly express glucocorticoid receptors and
show minimal levels of ERα expression in vivo.
The brain can synthesize hormones de novo from cholesterol or
metabolize circulating hormone precursors, like DHEA, into active
androgens and estrogens, which have important roles in the homeostasis of
the CNS. Steroid-converting enzymes are expressed in the various cell types
of the brain, and although steroid metabolism has been implicated in the
brain’s response to injury, the participation of microglia in this process has
not been described.
Given the protective properties of neurosteroids and the critical role
that microglia play in neurodegeneration, in the latter part of this dissertation
I formed the hypothesis that microglia are active contributors in the
synthesis and metabolism of neurosteroids in the brain. To test this
hypothesis I examined the expression and function of the major steroid
converting enzymes in the steroidogenesis pathway through real-time PCR
of ex vivo and in vitro microglia samples, and analyzed the function of these
enzymes with metabolic assays in primary microglia cultures.
24
I further characterized a developing neuronal cell line to test its
responsiveness to estrogen and other neurosteroids produced by microglia.
My studies focused on the parenchymal, slow-turnover, resident microglia
population. A novel role of microglia in relation to the effects of steroid
hormones in the brain is presented in this dissertation. Microglia cells are
shown to express various steroid-metabolizing enzymes, which mediate
events such as the autocrine re-activation of glucocorticoids, or the
production of active androgens and estrogens from steroid hormone
precursors, which can influence neuronal and other brain cells.
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CHAPTER 2
MODELS FOR STUDYING HORMONAL REGULATION
OF MICROGLIA ACTIVATION
Steroid hormones simultaneously affect many cell types throughout
the central nervous system (CSN) (Garcia-Segura, Chowen et al. 1994;
McEwen 2001; Behl 2002; Bryant, Sheldahl et al. 2006). One cell type that
has not been thoroughly evaluated for its susceptibility to steroid hormones
is microglia. Microglia are related to the monocytic/macrophage lineage of
immune cells (Raivich and Banati 2004); however they possess a distinctive
morphology and characteristics which set them apart as CNS-specialized
cells (Lawson, Perry et al. 1990; Walker 1999).  To determine if microglia
are targets of hormone action, they must be separated from other
surrounding cell types. A widely used approach is the isolation and culture
of enriched cell populations, which can also be transformed into
permanently viable cell lines. Assay systems can then be developed on
populations of these cells that allow for the systematic evaluation of end
points, which may be potentially regulated by hormones in microglia.
The activation of the innate immune system in the brain leading to
microglial expression of pro-inflammatory cytokines may be central to the
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pathophysiology and etiology of neurodegenerative disorders (Nguyen,
Julien et al. 2002; Lehnardt, Massillon et al. 2003). It is therefore, important
to develop microglia models that can inform us of potential factors
regulating the inflammatory response in these cells. In this section, I
developed microglia cultures and characterized their activation by bacterial
lipopolysaccharides (LPS). Granulocyte-monocyte colony stimulating factor
(GM-CSF) cultured cells had the highest proliferation rates, maintained
steady expression of macrophage/microglia markers, and showed a robust
cytokine response after LPS stimulation.
For this thesis, I initially used the mouse microglia cell line, BV-2, as
a model to determine whether the sex hormone 17β-estradiol (E2) could
block production of inflammatory factors by activated microglia, since there
were reports of such interactions in the literature (Mor, Nilsen et al. 1999;
Bruce-Keller, Keeling et al. 2000; Drew and Chavis 2000; Vegeto,
Bonincontro et al. 2001). The BV-2 cell line was originally generated by
infecting primary microglial cell cultures with a v-raf/v-myc oncogene
carrying retrovirus (Blasi, Barluzzi et al. 1990). This cell line will further be
referred to as BV-2 cells. While cloned cell lines offer ease of
experimentation, it is generally considered that microglia cell lines express
partially activated phenotypes (Carson, Reilly et al. 1998; Nakamura, Si et
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al. 1999; Aloisi 2001), and are not an authentic representation of the in vivo
phenotype. Thus, to verify the authenticity of results found in BV-2 cells and
to have a more reliable model, I also developed the use of primary microglia
cultures. In this Chapter I describe the establishment of the assay systems
used to evaluate hormonal regulation of microglia.
LPS stimulation as a model of neuro-inflammation in microglia
LPS is recognized as a potent activator of all macrophage cells,
including microglia (Nakamura, Si et al. 1999). LPS acts through the innate
immune pathway, comprised of evolutionarily conserved receptors called
Toll-like receptors (TLRs), which detect and alert the immune system of
invading pathogens (Iwasaki and Medzhitov 2004; Takeda and Akira 2005).
TLR-4, coupled to the accessory protein MD2, and CD14, a myeloid
phospholipid-anchored membrane protein, form the specific receptor for
LPS (Palsson-McDermott and O'Neill 2004; Miller, Ernst et al. 2005). Upon
ligand binding, TLR4-MD2-CD14 engages a signaling cascade that activates
many transcription factors, especially NFkB, which mediate the expression
of inflammatory genes (Doyle and O'Neill 2006). LPS has been used to
characterize microglia activation (Nakamura, Si et al. 1999).
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To establish LPS as a model for the activation of microglia, I
characterized the response to LPS in the BV-2 cells. LPS stimulation of BV-
2 microglia induced slight morphological changes, increased adherence, and
proliferation of these cells (Fig.3), as well as the production of cytokines. I
initially chose to measure 3 inflammatory cytokines and the generation of a
reactive oxygen species as endpoints reflecting LPS-induced activation of
microglia; these were: tumor necrosis factor-α (TNFα), interleukin-6 (IL-6),
interleukin-1β (IL-1β), and nitric oxide (NO).
The results of these studies showed that LPS stimulation of BV-2 cells
induced a time and dose-dependent production of TNFα, IL-6, IL-1β, and
NO (Fig.4) into the cell culture supernatants. Based on these experiments I
chose to use a dose of 100ng/ml LPS for subsequent stimulations. Each
cytokine had a particular time course, TNFα being the earliest cytokine
produced, followed by IL-1β, IL-6, and finally NO (Fig.4E). Secreted IL-1β
levels were low (pg/ml range) (Fig.4C, E), maybe due to inadequate
induction of caspase-1 activity required for its secretion (Thornberry, Bull et
al. 1992). Thus, Western blot analysis was used to evaluate IL-1β
production. These experiments showed that LPS induced a robust production





revealed low levels of mature processed cytokine of 28kDa (Fig.5B).
Resting BV-2 cells showed no detectable cytokine production.
 Primary culture of microglia
To further extend my working model for the activation of microglia,
and its potential regulation by steroid hormones, I developed primary
microglia cultures from neonatal mouse brains. Primary cultures were
derived from the transgenic mouse line p7.2fms-EGFP (C57BL6/6 X CBA
background). This transgenic mouse expresses EGFP, a green fluorescent
protein originally cloned from the jellyfish Aequorea victoria, controlled by
the promoter and regulatory elements of the macrophage colony stimulating
factor receptor gene, cfms (Sasmono, Oceandy et al. 2003). The cfms gene is
exclusively expressed in the monocyte cell lineage, which includes all tissue
macrophages and microglia (Sasmono, Oceandy et al. 2003; Sierra,
Gottfried-Blackmore et al. 2007), providing a clear and reliable source for
the isolation of highly enriched microglia cultures. Additionally, results from
primary cultures of these mice can subsequently be validated in vivo, given
that microglia are easily detected by immunofluorescence, or isolated by
FACS from the tissue by the endogenous expression of EGFP (Sierra
Submitted).
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Protocols for primary culture of microglia were first developed by
Giulian & Baker (1986) and Frei et.al. (1986) (Frei, Bodmer et al. 1986;
Giulian and Baker 1986). Ex vivo isolated adult microglia have a tendency to
undergo cell death after a dew days in culture and present low proliferative
capacity in vitro (Fischer and Reichmann 2001). The use of early post-natal
brains is favored because of high cell proliferation rates, and preparations at
this stage of development present negligible levels of contaminating viable
neuronal cells (McCarthy and de Vellis 1980). Therefore, I chose to use day-
2 old neonatal mouse pups for primary cell cultures. Forebrains were
extracted, meninges removed by micro-dissection, and tissue homogenized
by mechanical dissociation and cell straining. Cells were then plated and
cultured for up to 2 weeks. This method yields a stratified, mixed, culture of
astrocytes, oligodendrocytes and microglia (Giulian and Baker 1986).
I tested two methods for isolating microglia cells from the mixed glial
culture. The first was a method based on mild trypsinization of the astrocyte
layer, yielding an enriched population of adherent microglia on the culture
flask (Saura, Tusell et al. 2003). This method yielded an average of
0.05±0.01x106 cells / mouse brain. The low yield of cells obtained from this
method were mainly due to the fact that microglia attached to the tissue
culture flasks after removal of the astrocyte layer were very difficult to
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detach, even with prolonged trypsin incubations and vigorous shaking. The
second, and most commonly used, is the shaking method in which loosely
adherent microglia cells proliferating on top of the astrocyte layer are
detached and collected in the culture media (Giulian and Baker 1986). This
method yielded an average of 0.28±0.01x106 cells / mouse brain, which
proved to be greater than the mild trypsinization method.
Use of colony stimulating factors for primary microglia culture
Hematopoeitic cytokines, particularly the colony stimulating factors
macrophage-colony stimulating factor (MCSF) and granulocyte-macrophage
colony stimulating factor (GM-CSF) are able to induce proliferation and
differentiation of microglia cells (Giulian and Ingeman 1988; Saura, Tusell
et al. 2003; Ponomarev, Novikova et al. 2005). To determine the optimal
culture conditions I examined the effects of these growth factors on primary
microglia. In the mixed glial cultures microglia proliferation was augmented
by MCSF or GM-CSF (Fig.6A-C), increasing the yields of isolated
microglia, particularly by the shaking method (Fig. 6D).
A notable difference was observed in the morphology of MCSF and
GM-CSF grown cells (Fig.6B, C). MCSF induced the elongation and
ramification of adherent microglia (Fig.6C), where as GM-CSF induced an
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amoeboid morphology (Fig.6B). These results are consistent with previous
reports (Santambrogio, Belyanskaya et al. 2001). In spite of morphological
changes, the expression of the monocyte/macrophage marker, CD11b, was
not affected (Fig.7). GM-CSF is reported to induce a dendritic cell (DC)-like
phenotype in primary microglia (Fischer and Reichmann 2001;
Santambrogio, Belyanskaya et al. 2001; Ponomarev, Novikova et al. 2005).
However, under my culture conditions, the use of GM-CSF did not induce a
DC-like phenotype, as assessed by the expression of two DC-specific
surface antigens, CD11c, which was negative, and DEC-205, which showed
a marginal increase in expression (Fig.7B). The difference between my data
and published reports may be due to multiple factors such as the mouse
strain, source of GM-CSF (recombinant purified protein vs produced by a
transformed cell line) and / or the dose and time of incubation. Longer
incubations with GMCSF were not used because proliferation rates
decreased (Fig.6D).
Purity of microglia preparations
Since microglia were cultured with astrocytes and oligodendrocytes,
exclusion of these cells from the experiments in 1°MG cultures was vital.




by EGFP expression and by FACS analysis. Shaken 1°MG showed 99-98%
purity by EGFP expression and FACS analysis (Fig.7). Therefore, the results
obtained from the assays presented below can be attributed to microglia.
LPS activation of primary microglia
In this study, LPS stimulation of primary microglia led to the rapid
(30 minutes) activation of NFkB, observed by its translocation to the nucleus
by immunocytochemical analysis (Fig.8A). The stress-activated MAP kinase
p38, another important transcription factor involved in inflammation (Lee
and Young 1996), was also rapidly activated by LPS, through its
phosphorylation and consequent translocation to the nucleus observed
through immunofluorescence analysis and Western blotting (Fig.8B, C). I
next analyzed the production of inflammatory cytokines and NO in primary
microglia cultures.
MCSF and GM-CSF cultures stimulated with LPS alone showed a
limited production of NO (3-5mM vs 60-80mM of BV-2 cells), consistent
with previous reports of low NO responses to LPS alone in primary
microglia (Saura, Tusell et al. 2003). Interferon-γ (INFγ) can synergize with
LPS and stimulate the production of NO (Ding, Nathan et al. 1988; Chan
and Riches 2001; Saura, Tusell et al. 2003; Powell, Boodoo et al. 2004).
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Therefore, INFγ was added to LPS for the activation of primary microglia.
When stimulated with LPS+INFγ for 24hr, GM-CSF enriched microglia
produced significantly higher levels of NO, and showed similar levels of
TNFα and IL-6 compared to MCSF derived cells (Fig.9A).
The production of cytokines by primary microglia in response to 24hr
LPS+INFγ was also dose-dependent, with a mid range 100ng/ml LPS +
10ng/ml INFγ (Fig.9B). Notably, primary microglia produced less TNFα
and NO than BV-2 cells. The most reproducible and robust cytokine
responses were obtained from GM-CSF cultured microglia.
In addition to TNFα, IL-6 and NO, LPS+INFγ stimulation of 1°MG
caused an increase in other inflammatory cytokines and chemokines such as
IL1β, interleukin-12 (IL-12), monocyte chemo-attractant protein-1 and -5
(MCP-1, MCP-5), the small chemokine RANTES (Regulated upon
Activation, Normal T-cell Expressed, and Secreted), and the secreted TNF
receptor-1 (sTNFR1) (Fig.10). Therefore GM-CSF cultured microglia
obtained by the shaking method were used for the experiments presented in
the following chapters of this thesis; namely, the effects of steroid hormones
on microglia activation (Chapter 3), the autocrine involvement of microglia
on the actions of glucocorticoids (Chapter 4), and the expression and activity





Microglia cell cultures have been widely utilized for a variety of
studies as they offer a way of assessing the specific effects of any given
stimulus / manipulation, in the absence of compounding responses from
other cell types. Different microglia cell lines have been established from
mouse, rat and even human cells [examples can be noted in (Blasi, Barluzzi
et al. 1990; Cheepsunthorn, Radov et al. 2001; Nagai, Mishima et al. 2005)],
which have provided useful data for further validations in primary culture,
and in vivo. One example is the initial description of purinergic receptors in
microglia cell lines (Ferrari, Villalba et al. 1996). These studies led to further
functional descriptions of these receptors in microglia cultures (Visentin,
Renzi et al. 1999; Kaya, Tanaka et al. 2002; Gendron, Chalimoniuk et al.
2003) and in models of neuronal injury (Sasaki, Hoshi et al. 2003; Franke,
Gunther et al. 2004); finally leading to in vivo imaging studies describing the
chemo-attractant functions of these ATP receptors in microglia (Davalos,
Grutzendler et al. 2005; Haynes, Hollopeter et al. 2006).
In this Chapter I have utilized BV-2 cells and primary microglia
cultures to establish a model for studying microglia activation and
establishing reliable end-points, which may be regulated by steroid
hormones. The results presented here show that primary microglia cultures
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can be reliably activated by LPS+INFγ . Additionally, the use of
hematopoeitic growth factors such as GM-CSF, induced high proliferation
rates in the mixed microglia cultures without changing the expression of the
monocytes/macrophage marker CD11b nor inducing a dendritic cell
phenotype. Moreover, GM-CSF enriched microglia showed steady cytokine
responses after LPS+INFγ stimulation, which were similar to those of
MCSF-cultured microglia with the exception of NO. These findings are in
contrast to reports showing microglia exhibit different cytokine responses to
LPS if grown in MCSF or GM-CSF (Fischer, Bielinsky et al. 1993).
However, authors in this report used 10-fold higher concentrations of the
growth factors to find cytokine differences, while my objective in using
these growth factors was to increase proliferation without necessarily
changing the microglia phenotype. For their increased proliferation and
steady cytokine production, GM-CSF enriched microglia were selected as
the optimal culture/activation conditions for primary microglia culture.
To monitor microglia activation in subsequent studies, I chose two
main cytokines and a nitrogen radical, which have key roles in
neuroinflammation: TNFα, IL-6, and NO. TNFα  is implicated in the
development of CNS inflammation, by causing expression of chemokines
and its actions on the vascular endothelium leading to the infiltration of
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blood leukocytes [rev by (Aloisi 2001)]. TNFα  is also essential for the
activation of parenchymal microglia during endotoxaemia, and can be
detrimental to the brain by promoting apoptosis of oligodendrocytes and
preventing remyelination, and by augmenting cell death in models of
neurodegeneration [rev by (Rivest 2003)]. TNFα is also a potent inducer of
IL-1β, PGE2 and IL-6. IL-6 induction is considered a ubiquitous and early
marker of tissue damage in the brain and plays a central role in the activation
of astrocytes [rev by (Raivich, Bohatschek et al. 1999; Raivich, Jones et al.
1999)]. Microglia derived IL-6 can interfere with production of new neurons
in the adult brain (Monje, Toda et al. 2003), but has also many neurotrophic
properties [rev by (Benveniste 1998)]. At low, physiological concentrations,
NO has various roles in the homeostasis of the brain [rev. by (Ohkuma and
Katsura 2001; Guix, Uribesalgo et al. 2005)]. However, overproduction of
NO has been implicated in most neurodegenerative diseases (Murphy 2000)
because of its neurotoxic properties (Dawson and Dawson 1996; Moreno-
Lopez and Gonzalez-Forero 2006).
The activation of microglia and subsequent expression of pro-
inflammatory cytokines may be central to the pathophysiology and etiology
of neurodegenerative disorders (Nguyen, Julien et al. 2002; Lehnardt,
Massillon et al. 2003). It is therefore, important to develop microglia models
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that can inform us of potential factors regulating the inflammatory response
in these cells. LPS produced a consistent cytokine response both in BV-2
microglia and in primary microglia cultures grown with MCSF or GM-CSF.
These systems were used as a platform to study the potential anti-




MICROGLIA EXPRESS HORMONE RECEPTORS THAT CAN
MODULATE THEIR LPS ACTIVATED RESPONSES
The neuroprotective and anti-inflammatory effects of E2 in the brain
have been widely reported (Wise, Dubal et al. 2000; Behl 2002; Liao, Chen
et al. 2002; Vegeto, Belcredito et al. 2003; Wen, Yang et al. 2004; Hoffman,
Merchenthaler et al. 2006). In vitro studies have claimed that E2 can act
directly on microglia cells to block synthesis of inflammatory molecules.
Contrary to these reports, other findings indicate that E2 has no effects [rev.
in Chapter 1]. To clarify whether microglia cells are direct targets of E2 and
are active mediators of E2 effects in the brain, the expression of estrogen
receptors in microglia was studied. These studies were done in collaboration
with Dr. Amanda Sierra (Stony Brook, NY), a former postdoc in the
McEwen laboratory, who developed a system for isolation of microglia from
adult cfms-EGFP mice using fluorescence-activated cell sorting (FACS) to
measure gene expression. Estrogen receptor studies were also conducted in
48
collaboration with Dr. Teresa Milner (Cornell Medical School, NY) with
whom an ultrastructural analysis by electron microscopy was carried out.
I then proceeded to utilize BV-2 microglia and cfms-EGFP mouse-
derived primary microglia cell cultures stimulated with LPS to determine
whether microglia activation is affected by E2 and glucocorticoids.
Glucocorticoids are well-recognized regulators of immune cell activation
(Chapter 1) and were therefore, used as a positive control for comparison to
the effects of E2.
Expression of Steroid hormone receptors in microglia
Microglia cell lines are reported to express mRNA and protein for
both estrogen receptors (ERα and ERβ) (Bruce-Keller, Keeling et al. 2000;
Vegeto, Bonincontro et al. 2001).  However, few reports with primary
microglia cultures, and no in vivo studies with microglia have corroborated
that this cell type expresses estrogen receptors by conventional techniques
such as immunocytochemistry and in situ hybridization (Garcia-Ovejero,
Veiga et al. 2002; Sierra Submitted).
In collaboration with Dr. Sierra, microglia from adult cfms-EGFP
mice were isolated by FACS, which enabled us to analyze ex vivo the
expression of steroid receptor genes by real-time PCR (RT-PCR). Our RT-
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PCR results demonstrated that ex vivo isolated microglia express
glucocorticoid (GR) and mineralocorticoid (MR) receptors, as well as low
levels of ERα  mRNA. Additionally, we further described that in vivo
activation of microglia by i.p. LPS injections led to a down-regulation of
these receptors (Fig.11A) (Sierra Submitted). Furthermore, expression of
ERβ, androgen receptor (AR), or progesterone receptor (PR) was not
identified in resting or LPS-activated microglia (Sierra Submitted). Protein
levels of GR were validated by Western blot, but no ERα protein was
detected by this method, consistent with it’s low mRNA levels (Fig.11B).
In agreement with previous reports, we were unable to detect ERα
protein through conventional methods. For this reason, we established a
collaboration with Dr. Milner, who has done extensive work on the detection
of estrogen receptors in the brain at the ultrastructural level through electron
microscopy. The expression of ERα protein in microglia was studied in
dorsal hippocampal sections of cfms-EGFP female mice. Microglia were
initially visualized by DAB immunohistochemistry using an anti-GFP
antibody. Typical microglial processes were found in stratum radiatum of





Single labeling with a previously described anti-ERα  antibody
(Okamura, Yamamoto et al. 1992; Alves, Lopez et al. 1998; Milner,
McEwen et al. 2001) revealed the presence of ERα  protein in axons,
dendrites and glial processes (Fig.13), as reported previously (Milner,
McEwen et al. 2001).
For co-localization studies, microglia were identified with the anti-
GFP antibody, which was then detected with a species-specific (chicken)
secondary antibody conjugated to nano-gold particles; ERα was detected
with an anti-ERα  antibody and a species-specific (rabbit) secondary
antibody conjugated to horseradish peroxidase revealed by
diaminobenzidine (DAB) immunohistochemistry. Double staining of tissue
sections revealed rare double-labeled microglia profiles, with most ERα
labeling found on neuronal spines, terminals, and axons (Fig.13).
Nevertheless, in some instances, we did observe rare instances of double-
labeled microglia with ERα in the cytoplasm of cell processes (Fig.13C, D),
and near the cell nucleus (data not shown). A parallel study was done with
sections dually labeled for GFP and ERβ, in which no double-labeled
processes were detected (data not shown). These ultrastructural results are
consistent with our RT-PCR results showing that microglia express low
levels of ERα and do not express ERβ.
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To assess the functional relevance of steroid hormone receptors
expressed in microglia in the context of inflammation, BV-2 cells and
primary microglia cultures were treated with corticosterone or E2, and then
challenged with LPS+INFγ as detailed in Chapter 2.
E2 does not block the activation of p38 MAPK by LPS
An early event in the response of microglia to LPS is the activation of
inflammatory transcription factors, such as the p38 MAPK (Lee and Young
1996). Microglia cells were pre-treated with 10nM E2 for 30 minutes and
then stimulated with LPS for an additional 30 minutes. LPS-induced p38
MAPK phosphorylation was not significantly reduced by E2 in primary
microglia (n=4) (Fig.14A), nor in BV-2 microglia (n=7) (data not shown)
[Note: n= the number of independent experiments done in triplicate]. E2 also
failed to prevent the nuclear translocation of phospho-p38 MAPK in primary
microglia (Fig.14B). Preliminary studies with LPS-induced NFkB nuclear
translocation in primary microglia showed a similar lack of E2 effects (not
shown). Conversely, LPS-induced phosphorylation of p38MAPK was
diminished by a 30 minute pre-treatment with 1µM corticosterone (52.69 ±
1.91%) (n=2) (p=0.05) (Fig.14A, C).
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Corticosterone, but not E2, blocks the production of inflammatory cytokines
in microglia
Cytokines are the principal mediators of microglia-induced
inflammation, and therefore, a critical therapeutic target. Initial studies with
LPS-stimulated BV-2 microglia showed that E2 pre-treatment had no
consistent effect on production of TNFα , IL-6 or NO under various
conditions tested [E2 10nM (n=3), 1uM (n=2), 10pM (n=2); pre-treatments
3hr (n=2), 24hr (n=1), 10 min (n=2)] (data not shown). Therefore, primary
cultures of microglia cells were tested with corticosterone or E2 and then
challenged with LPS+INFγ  to elicit the expression of inflammatory
cytokines (Chapter 2). Corticosterone was used as a positive control in these
experiments, given its reported anti-inflammatory effects (McKay and
Cidlowski 1999; Nadeau and Rivest 2003), and our findings showing
predominant expression of GR in microglia compared to other steroid
hormone receptors (Sierra Submitted).
We tested the effects of corticosterone and E2 over a wide range of
concentrations (10pM, 10nM, and 1µM) (Bruce-Keller, Keeling et al. 2000;
Ghisletti, Meda et al. 2005; Jacobsson, Persson et al. 2006). After 24hr,
LPS+INFγ induced the secretion of the pro-inflammatory cytokines TNFα,
IL-6 as well as NO, which were not detectable in the absence of LPS+INFγ
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or with hormone treatment alone (Chapter 2). Corticosterone at the low dose
(10nM) showed a trend to decrease the production of TNFα secreted by
microglia (Fig.15A) by 16.91 ± 9.5% (n=8) (n.s.); while a higher
concentration (1µM) of glucocorticoid reduced TNFα secretion by 53.72 ±
4.62% (n=15)  (p<0.001). TNFα secreted by microglia remained unaffected
by E2 over the entire range of concentrations tested (Fig.15).
The low concentration of corticosterone had no significant effect on
IL-6 expression, while the high dose of corticosterone (1µM) significantly
prevented the induction of IL-6 by 45.02 ± 3.75% (n=15) (p<0.001)
(Fig.15B). The low concentration of E2 (10pM) produced a similar, but
smaller decrease in IL-6 production of 14.55 ± 6.34% (n=4) (p=0.01). At a
higher dose (10nM), E2 had no significant effect; yet at the highest dose
(1µM) it produced a small but significant increase (16.91 ± 4.97% (n=7)
(p=0.004) (Fig. 15B). The production of NO was reduced by corticosterone
(1µM) by 25.46 ± 3.03% (n=15) (p<0.001) (Fig. 15C), whereas E2 was






E2 does not induce rapid phosphorylation of p44/42 MAPK
The p44/42 extracellular regulated mitogen activated protein kinase
(ERK MAPK), a mediator of multiple signaling pathways, plays an
important role in brain responses to injury (Pearson, Robinson et al. 2001;
Irving and Bamford 2002; Hetman and Gozdz 2004). In the brain, p44/42
MAPK is a main mediator of E2’s neuroprotective effects (Bryant, Sheldahl
et al. 2006). To determine if E2 could induce p44/42 MAPK activation in
microglia, BV-2 cells or primary microglia cultures were acutely treated
with E2 and p44/42 phosphorylation levels were measured by Western blot.
E2 did not induce the phosphorylation of p44/42 MAPK in BV-2 microglia,
even over a wide range of E2 concentrations [10pM (n=2), 1nM (n=2),
10nM (n=7), 1µM (n=2)] and time points of incubation (5 to 60 minutes)
(data not shown). Some experiments showed a stimulatory effect of E2, but
these were inconsistent, non-reproducible, and sometimes opposite. In
primary microglia, E2 [10nM, 15min, (n=6)] consistently showed no effect
on p44/42 phosphorylation levels (Fig. 16).
In view of the limited effects found with E2, and predominant effects
exerted by corticosterone in primary microglia, I assessed the expression of
ERα and GR in these cells by Western Blot. Primary microglia showed no
detectable levels of ERα  when cultured with regular media or in the
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presence of MCSF or GM-CSF (Fig.17A). However, primary microglia had
strong expression of GR (Fig. 15). GR protein levels were not regulated by
LPS+INFγ stimulation (Fig. 17B). Primary microglia, both in resting state or
after LPS+INFγ stimulation, were negative for ERβ (data not shown), as
found in ex vivo microglia (Sierra in preparation).
Discussion
E2 anti-inflammatory effects are not mediated through MG
The data presented above indicate that microglia express
glucocorticoid and mineralocorticoid hormone receptors. However, for the
sex steroids, only ERα was expressed, whereas ERβ, androgen receptor and
progesterone receptor were not. Recently, a membrane bound, G-protein
coupled receptor for E2 has been described (GPR30) (Pedram, Razandi et al.
2006), yet no reports have examined its expression in microglia.
Expression of ERα was low in microglia, which was reflected by our
inability to detect the protein by Western blot and immunohistochemistry.
Indeed, the expression of sex hormone receptors in microglia has been a
controversial issue, since their detection by conventional
immunohistochemistry or in situ hybridization in the adult brain remained
inconclusive (10, 19, 32). A main compounding factor in these studies may
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be the low expression levels of these receptors coupled to their non-nuclear
localization (Sierra, et al 2007). ERα detection was possible by electron
microscopy ultrastructural analysis, which revealed only rare labeling of
ERα in microglia profiles (Sierra, et al, 2007). Non-nuclear localization of
ERα has been described for CA1 neurons of the hippocampus, which is also
not detectable by light microscopy (Milner, McEwen et al. 2001).
Non-nuclear estrogen receptors are implicated in MAPK activation,
yet in BV-2 cells and in primary microglia E2 failed to modulate basal
p44/42 MAPK phosphorylation levels. My findings are both in agreement
and in disagreement with previous reports with different microglia cell lines
(Bruce-Keller, Keeling et al. 2000; Baker, Brautigam et al. 2004).
The low levels of ERα expression are consistent with my results
showing the inability of E2 to exert significant anti-inflammatory effects on
microglia, as assessed by p38 MAPK activation and the production of
TNFα, IL6, and NO. As discussed in the Introduction, reports on E2 effects
on activated microglia in vitro are inconsistent. Culture conditions, species
from which primary cultures are obtained, and transformation of cell lines
could be factors contributing to such discrepancies. However, we further
have reported that in vivo E2 did not regulate the microglial expression of
IL-6, TNFα , TGFβ1 mRNAs (Sierra Submitted). Therefore, the low
64
expression of ERα in microglia may play a yet unidentified role in these
cells. Another possible explanation to the results presented here is that E2
may synergize with other, as of yet unidentified factors, to affect microglia
cells. This could be explored by others in future studies.
E2 has widely reported neuroprotective and anti-inflammatory effects
in the brain (Lee and McEwen 2001; Vegeto, Ciana et al. 2002). Based on
the findings presented here, in which ERβ is not expressed and ERα  is
expressed at low levels in microglia, I propose that the anti-inflammatory
effects of E2 observed in the brain in vivo are mediated by cell types other
than microglia. Supporting this model, several groups have reported the
expression of ERs, and corroborated the effects of E2, in cells involved in
the brain’s inflammatory response such as astrocytes (Azcoitia, Sierra et al.
1999; Sortino, Chisari et al. 2004; Dhandapani and Brann 2006), endothelial
cells (Langub and Watson 1992; Galea, Santizo et al. 2002; Stirone, Duckles
et al. 2003), and infiltrating leukocytes (Offner 2004; Shim, Gherman et al.
2006; Stygar, Westlund et al. 2006).
Glucocorticoids play a primary role in MG regulation
Microglia activation by LPS+INFγ was inhibited by corticosterone,
supporting our findings that GR is the predominant steroid hormone receptor
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expressed in these cells at both the mRNA and protein level (Sierra
Submitted). Glucocorticoids play an essential role in protecting the brain
against an inflammatory challenge (Sorrells and Sapolsky 2007). For
instance, the GR agonist dexamethasone increases the survival of
dopaminergic neurons after intranigral injection of bacterial
lipopolysaccharides (LPS), while the GR/PR antagonist RU486 induces a
dramatic degeneration (Castano, Herrera et al. 2002). The results presented
in this Chapter support a model where glucocorticoids, and not E2s, are the
main regulators of activated microglia. A more detailed description of the
actions of glucocorticoids on brain inflammation is presented in the
following chapter (Chapter 4).
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CHAPTER 4
NEUROENDOCRINE MICROGLIA – LOCAL AMPLIFICATION
OF GLUCOCORTICOIDS
In the previous chapter I presented evidence indicating that
glucocorticoids, namely corticosterone, are the main steroid hormone
regulating microglia activation. Glucocorticoids, cortisol in humans and
corticosterone in rodents, are presumably the body’s most effective
regulators of inflammation, exerting permissive, stimulatory, and
suppressive effects [rev by (Munck, Guyre et al. 1984; McEwen 1997;
Yeager, Guyre et al. 2004)]. Systemic inflammation induces a surge in
circulating glucocorticoids as a result of hypothalamic-pituitary-adrenal
(HPA) axis activation by cytokines (Beishuizen and Thijs 2003). This surge
of glucocorticoids is required for survival in experimental animals
challenged with antigens, bacterial lipopolysaccharides (LPS), or tumor
necrosis factor-α  (TNFα) [rev by (Chapman, Gilmour et al. 2006)].
Glucocorticoids regulate inflammation by altering the distribution and
trafficking, as well as differentiation and maturation, of
monocytes/macrophages, neutrophils and granulocytes (McEwen 1997;
Ashwell, Lu et al. 2000). Additionally, they suppress pro-inflammatory gene
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transcription and promote expression of anti-inflammatory cytokines
(Barnes 1998).
The effects of glucocorticoids follow a bell-shaped curve, showing
permissive/stimulatory actions at physiological concentrations, while
exerting suppressive effects at pharmacological doses (Munck and Naray-
Fejes-Toth 1992; Sapolsky, Romero et al. 2000). In this way, physiological
concentrations of glucocorticoids facilitate the initiation of inflammatory
responses, and at supra-physiologic concentrations, achieved through HPA
axis activation, glucocorticoids mediate anti-inflammatory actions to prevent
an unregulated, and potentially lethal, inflammatory response [rev by
(Chapman, Gilmour et al. 2006)].
For the inflammatory response to be effectively resolved, or
perpetuated, the actions of glucocorticoids require specific targeting to the
site of inflammation to exert their proper function. Regulatory targeting
mechanisms include changing the affinity of glucocorticoid binding proteins,
modulating the expression and/or affinity of glucocorticoid receptors (GR),
and/or metabolically activating or inactivating glucocorticoids within the
target cell [rev by (Rook, Baker et al. 2000)].
Glucocorticoids can enzymatically be activated or inactivated,
between their C11-hydroxyl to their C11-ketone forms respectively, by two
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distinct enzymes known as 11β-hydroxysteroid dehydrogenase (11βHSD)
type 1 and type 2 [rev by (Seckl and Walker 2001; Tomlinson and Stewart
2001)]. 11βHSD-2 is a dehydrogenase, inactivating corticosterone (cortisol
in humans) into 11-dehydro-corticosterone (cortisone in humans). 11βHSD-
2 is predominantly expressed in mineralocorticoid target tissues, such as the
kidney collecting tubules, colon and sweat glands, or tissues requiring
protection from glucocorticoid actions, such as the placenta and developing
brain (Brown, Diaz et al. 1996; Diaz, Brown et al. 1998). On the other hand,
11βHSD-1 acts predominantly in vivo and within cells, as an oxido-
reductase, catalyzing the re-activation of corticosterone (cortisol in humans)
from its 11-keto derivative (cortisone in humans) (Seckl and Walker 2001).
Thus, cells expressing 11βHSD-1 increase the levels of available
glucocorticoids for GR activation, whereas cells expressing 11βHSD-2 are
glucocorticoid resistant.
In the 11βHSD-1 null mouse, glucocorticoid–mediated responses are
attenuated (Kotelevtsev, Holmes et al. 1997), consistent with the model that
11βHSD-1 activity contributes significantly to the pool of intracellular
active glucocorticoids (Seckl and Walker 2001; Morris, Brem et al. 2003).
Although this role of 11βHSD-1 in the metabolic actions of glucocorticoids
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has been clearly established, its role in the immune response has, until
recently, remained unclear.
Initial studies with 11βHSD inhibitors suggested a role for these
enzymes in immunity, yet it remained unclear whether the results pertained
to 11βHSD-1 or 11βHSD-2 activity [rev. by (Chapman, Gilmour et al.
2006)]. Currently, 11βHSD-1 expression and activity has been detected in
the principal cells of the immune system: monocytes, macrophages,
dendritic cells, B and T lymphocytes, both in human and mouse [rev. by
(Chapman, Gilmour et al. 2006)]. 11βHSD-1 null mice show a delay in
acquisition of macrophage phagocytic capacity (Gilmour, Coutinho et al.
2006). Furthermore, a consistent pattern has emerged in which pro-
inflammatory mediators, particularly TNFα and IL-1β, increase 11βHSD-1
expression to increase local glucocorticoid availability and hence, promote
local anti-inflammatory action (Chapman, Gilmour et al. 2006; Hardy, Filer
et al. 2006).
11βHSD-1 is predominantly expressed in metabolically active tissues
such as the liver, adipose tissue, bone, gonads, and the brain (Moisan,
Edwards et al. 1992; Seckl and Walker 2001). Many brain areas are rich in
11βHSD-1 expression, notably the hippocampus, cerebellum, and neocortex
(Moisan, Seckl et al. 1990). It has been proposed that 11βHSD-1expression
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in the brain plays roles in cognitive function, neuroprotection, and
contributes to the negative feedback of glucocorticoids on HPA activity [rev
by (Holmes, Yau et al. 2003)]. However, elevated or prolonged levels of
glucocorticoids are neurotoxic to injured neurons (Reagan and McEwen
1997), and to our knowledge, no studies have addressed whether brain
11βHSD-1 expression plays a role in neuroinflammation.
Therefore, given that un-regulated microglia-mediated inflammation
contributes greatly to neurodegeneration [rev in Chapter 1], and in view of
the regulatory effects of glucocorticoids on microglia (Chapter 3), in the
present Chapter of this thesis I tested the hypothesis that microglia express
glucocorticoid converting enzymes 11βHSD type 1 and type 2, which
modulate the actions of glucocorticoids in the CNS. To this end, I analyzed
11βHSD type 1 and type 2 mRNA expression by real-time PCR, and protein
by immunofluorescence of brain tissue sections and Western blots of
primary cultures. Additionally, the function of these enzymes was studied in
primary microglia cultures using tritiated substrates. The expression and
function of 11βHSDs were examined both in resting and activated microglia.
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Microglia cells express functional 11βHSD-1
Expression of 11βHSD-1 and 11βHSD-2 mRNA was analyzed by
real-time PCR (RT-PCR) in microglia isolated from adult cfms-EGFP mice
by fluorescence-activated cell sorting (FACS) (ex vivo MG). 11βHSD
expression was also assessed in primary cultures derived from neonatal
mouse brains (1°MG) (Fig.18). Adrenal and ovary tissue samples were used
as positive controls. Specific gene cycle threshold (Ct) values were
normalized to Ct values of L27A, a ribosomal housekeeping gene, and
converted to percentage using adrenal values as 100% for 11βHSD-1
(Fig.18A) and ovary as 100% for 11βHSD-2 (Fig.18B). Ex vivo MG and
primary microglia expressed low levels of 11βHSD-1 compared to adrenals
and ovary (Fig.18A), and no significant differences were found in the
expression levels of 11βHSD-1 between ex vivo MG and primary microglia
(Fig. 18A). On the other hand, 11βHSD-2 expression was almost
undetectable in microglia samples (Fig.18B). Although both enzymes were
expressed at low levels, further comparison of 11βHSD expression values in
microglia showed that 11βHSD-1 is the main enzyme expressed (Fig.18C).
This was further corroborated by Western Blot analysis of primary microglia
showing a specific 11βHSD-1 immunoreactive band of predicted molecular
weight (36kDa) (Fig.18D). 11βHSD-1 protein expression in microglia was
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low compared to liver (Fig.18C). 11βHSD-2 was not evaluated by Western
blot, however the possibility of its presence was analyzed in the functional
assays that follow.
To evaluate the possible function of 11βHSD-1 and 11βHSD-2,
1°MG cells were incubated with the tritiated substrates H3-11-dehydro-
corticosterone (11-DH-Cort) or H3-corticosterone (Cort). The conversion of
these steroids, from their 11-hydroxyl to 11-keto forms or vice versa, was
analyzed by thin layer chromatography (Fig.19). 1°MG showed specific
11βHSD-1 conversion of 11-DH-Cort to Cort. Scanning of the TLC plate
revealed only two peaks of radioactivity, indicating cells did not produce
any other metabolites from 11-DH-Cort (Fig. 19A). To estimate the activity
levels of 11βHSD-1, a time-course incubation with 11-DH-Cort was
conducted with primary microglia. Conversion of 11-DH-Cort to Cort was
time-dependent, observed as early as 3hr (57.8±2.3%, p<0.05), with
substrate depletion by 12hr (85.6±0.2%, p<0.05) (Fig.19B). In contrast,
1°MG showed no 11βHSD-2 conversion of Cort to 11-DH-Cort (Fig.19C)
suggesting that the 11βHSD-2 enzyme is absent in microglia. The specificity
of 11-DH-Cort conversion to corticosterone was verified by co-incubation of
the cells with an 11βHSD-1 inhibitor (11-keto-progesterone)
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(Latif, Pardo et al. 2005). Treatment of 1°MG with 11-keto-progesterone
completely blocked the 11βHSD-1 conversion of 11-DH-Cort to Cort
(Fig.19D).
11-dehydro-corticosterone blocks cytokine production via 11βHSD-1
activity in 1°MG
To assess the functional relevance of 11βHSD-1 expression in
microglia, 1°MG cultures were stimulated with LPS to elicit the production
of pro-inflammatory cytokines and the anti-inflammatory effects of 11-
dehydro-corticosterone were compared to corticosterone. At a range of
concentrations (5nM-5µM), 11-dehydro-corticosterone was equal to or even
more effective than corticosterone in blocking the production of the pro-
inflammatory cytokines TNFα  (IC5011C= 51nM vs IC50C= 62.6nM, p<0.0001)
(Fig.20A), IL-6 (IC5011C= 201.8nM vs IC50C= 232.4nM, p<0.0001) (Fig.20B), and
NO (IC5011C= 58.9nM vs IC50C= 67.5nM, p<0.0001) (Fig.20C).
Activated microglia increase expression of 11βHSD-1
Activation of peripheral macrophages and monocytes by pro-
inflammatory stimuli is reported to increase the expression of 11βHSD-1




activation of microglia also affected 11βHSD-1, mRNA expression of this
enzyme was analyzed by RT-PCR in 1°MG cultures treated with LPS+INFγ.
LPS+INFγ-activated microglia showed a 246±63-fold induction (p<0.01) in
11βHSD-1 expression (Fig.21A). To determine if 11βHSD-1 up-regulation
could also be induced by downstream mediators of inflammation, primary
microglia were stimulated with INFγ alone or microglia LPS-conditioned
media (LCM). INFγ and LCM did not affect 11βHSD-1 expression in 1°MG
(Fig.21A) indicating that LPS is a far more potent inducer of 11βHSD-1
mRNA expression than cytokines.
In spite of the increased mRNA levels of 11βHSD-1, there was no
increase in enzymatic activity when LPS+INFγ activated primary cultures
were incubated with H3-11-DH-corticosterone (data not shown). These
results suggest that other factors may be required for increased activity in
activated microglia.
To validate my findings from primary microglia in vivo, I next
analyzed by RT-PCR samples of FACS-sorted microglia from cfms-EGFP
adult male mice that were intraperitoneally (i.p.) injected with saline or LPS
for 24hr. This i.p. injection of LPS induces the activation of microglia as
observed by morphological changes and the expression of inflammatory
cytokines (Sierra, et al, 2007). RT-PCR analysis showed that LPS activation
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of microglia induced a robust increase in the expression of 11βHSD-1
(655±154 fold induction, p<0.01) (Fig.21B). This increase in 11βHSD-1
mRNA  expression was consistent with my findings in primary microglia.
In a parallel study to the above experiment, 30 µm serial sections were
collected from brains of perfused adult male cfms-EGFP mice following i.p.
saline or LPS injections (24hr). Preliminary 11βHSD-1 immunofluorescence
analyses indicated that in saline treated mice, 11βHSD-1 immunoreactivity
was prominent in non-EGFP cells with little to no staining in microglia cells
(assessed by co-localization with EGFP) (Fig.22A). Double-labeling
experiments with anti-11βHSD-1 and a marker for neurons (anti-NeuN),
astrocytes (anti-GFAP), or oligodendrocytes (anti-RIP) indicated that most
11βHSD-1 expression came from astrocytes (Fig.22B). After 24hr of LPS
injection, 11βHSD-1 staining remained at low levels in microglia cells
(Fig.22C). In sharp contrast, 11βHSD-1 immunoreactivity was greatly
down-regulated in astrocytes (Fig.23D). This pattern of staining was
observed at 48hr as well (data not shown), with an indication of returning
levels of 11βHSD-1 in non-EGFP cells, and microglia returning to a resting
phenotype, by day 5 after LPS challenge (data not shown).
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Glucocorticoids regulate 11βHSD-1 expression in microglia
In addition to inducing the activation of microglia, i.p. injection of
LPS causes circulating corticosterone levels to rise (Beishuizen and Thijs
2003; Nadeau and Rivest 2003). Acute treatments of glucocorticoids are
reported to increase 11βHSD-1 expression in the hippocampus. To assess
whether microglia 11βHSD-1 expression is regulated directly by
glucocorticoids, 1°MG cultures were treated with corticosterone.
Preliminary experiments indicated that direct stimulation of 1°MG with
corticosterone (1uM) did not significantly affect 11βHSD-1 expression
(Fig.23). Corticosterone treatment significantly reduces the LPS+INFγ-
activation of 1°MG, therefore, 1°MG cells were also treated with
corticosterone, LPS+INFγ or both. LPS+INFγ induced an expected increase
of 11βHSD-1 expression (406±63.4%, p<0.05) (Fig.23), and corticosterone
had no effect on this up-regulation (442.3±9.0%, p<0.01) (Fig.23). These
preliminary results indicate that acute, micromolar concentrations of
corticosterone do not affect 11βHSD-1 mRNA expression in microglia, and





In the present Chapter of this thesis I have described the expression
and activity of 11βHSD-1 in microglia, providing evidence that suggests an
active role for 11βHSD-1 in regulating brain inflammation through the re-
activation of glucocorticoids.
11βHSD-1 expression in Microglia
In the resting brain, preliminary immunofluorescence analysis
indicated that 11βHSD-1 expression was predominantly found in EGFP-
negative cells (possibly astrocytes and neurons), consistent with the
proposed house-keeping roles of glucocorticoids in the homeostasis of the
CNS [rev. by (McEwen 1997)]. In this chapter, 11βHSD expression and
activity in microglia cells is described for the first time. Although
preliminary findings suggest 11βHSD immunoreactivity is low in tissue
microglia, mRNA levels assessed in ex vivo FACS-sorted microglia were
high, and primary microglia cells showed the presence of mRNA, protein,
and a functional enzyme. The expression levels and activity of 11βHSD-1 in
microglia described here are comparable to other related cell types such as
human monocyte-derived macrophages, which exhibit 95% conversion in
24hr (Thieringer, Le Grand et al. 2001). My results are also similar to  those
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found in other cells that participate in local tissue inflammation, such as
TNFα stimulated synovial fibroblasts (Hardy, Filer et al. 2006) and skeletal
muscle cells (Jang, Obeyesekere et al. 2006), which show reductase activity
and substrate conversion with similar rates. However, the 11βHSD-1 activity
in microglia is considerably lower than the activity observed in highly
metabolic cells like hepatocytes, which exhibit 30% conversion in 30
minutes (Liu, Nakagawa et al. 2003), or that found in steroidogenic cells
such as testicular Leydig cells, which exhibit 95% conversion of substrate
within 30 minutes (private communication, Ge, et al.).
Although an increase in 11βHSD-1 mRNA was detected in activated
microglia, 11βHSD-1 activity was not changed. This may be due to rate-
limiting factors for 11βHSD-1 activity, which were not considered in the
experimental design. The catalytic activity of 11βHSD-1 is determined by
the redox potential set by the NADP+ to NADPH cofactor ratio, which is
modulated by hexose-6-phosphate dehydrogenase (H6PD) activity. H6PD
raises the intracellular level of NADPH favoring the reductase activity of
11ßHSD-1 observed in several tissues [rev by (Ge, Dong et al. 2005)].
Therefore, activity of H6PD and levels of NADPH in activated microglia
should be considered, especially as lack of G6PD can abrogate 11ßHSD-1
activity (Lavery, Walker et al. 2006).
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The adult brain presents expression of 11β-HSD-2 that is limited to
mineralocorticoid sensitive areas involved regulation of blood pressure and
salt appetite (Robson, Leckie et al. 1998). There is also low levels of 11β-
HSD-2 expression reported in selected nuclei of the hypothalamus, as well
as the amygdala, locus coeruleus and nucleus tractus solitarius (Robson,
Leckie et al. 1998). Almost undetectable levels of 11βHSD-2 mRNA were
observed in microglia, and no functional activity was present indicating
these cells do not catalyze the de-activation of glucocorticoids and are not
part of the brain population of cells expressing 11βHSD-2.
Modulation of 11βHSD-1 during neuroinflammation
High levels of glucocorticoids are deleterious to brain homeostasis,
therefore tight regulation of active glucocorticoids is important (Sapolsky
1996). Acute stress, or glucocorticoid treatment in rats, induces a rise in
hippocampal 11βHSD-1 expression (Jamieson, Fuchs et al. 1997; Jamieson,
Nyirenda et al. 1999), which plays a role in mediating the necessary negative
feedback on HPA activity [rev by (Holmes, Yau et al. 2003)]. However,
chronic stress decreases 11βHSD-1 expression (Seckl 1997), as a likely
neuroprotective mechanism to prevent the toxic metabolic effects of
glucocorticoid excess (Rajan, Edwards et al. 1996). The decrease of
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11βHSD-1 expression observed in non-EGFP cell in my studies may likely
be induced by pro-inflammatory stimuli, such as cytokines secreted by
microglia, and/or to the acute elevation of glucocorticoids following LPS
injection.
On the other hand, 11βHSD-1 mRNA up-regulation in activated
microglia following LPS challenge suggests these cells locally increase the
availability of active glucocorticoids following their activation. However,
previously we reported that under the same in vivo experimental paradigm,
glucocorticoid receptors are down-regulated by LPS activation (Sierra
Submitted). These apparently opposing effects of LPS in activated microglia
are reminiscent of the effects of glucocorticoids on immune cells, in which
cytokine production is inhibited, yet cytokine receptor expression is
increased (Sorrell, 2006). Alternately, given that systemic LPS injection
causes elevated corticosterone levels, the down-regulation of GR’s observed
in ex vivo MG could be due to autologous receptor down-regulation
(Burnstein and Cidlowski 1992; Oakley and Cidlowski 1993). This
prediction would be consistent with the fact that GR protein levels were
unaffected by LPS+INFγ in primary microglia, and my preliminary findings
showing that corticosterone does not down-regulate 11βHSD-1 mRNA
expression in LPS+INFγ stimulated microglia.
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Even with reduced GR expression, my results with primary microglia
indicate that in spite of LPS+INFγ activation, 11-DH-Cort was equal to or
more effective than Cort in blocking TNFα, IL-6 and NO production. This
maybe due to the fact that 11-DH-Cort is being converted to Cort within the
cells, where intracellular GRs are expressed. My results suggest that in
activated microglia GR-mediated anti-inflammatory effects are not being
compromised. Considering the down-regulation of 11βHSD-1 in astrocytes
and the possible increased expression in microglia (because protein levels
have not yet been seen to increase in vivo), my results indicate a role of
11βHSD-1 in gating glucocorticoid access to intracellular glucocorticoid
receptors (GR) within specific cell types.
The results presented indicate that local amplification of
glucocorticoids may be occurring at sites of neuro-inflammation through the
expression and activity of 11βHSD-1 in microglia. 11βHSD-1 activity may
be critical in boosting the anti-inflammatory effects of glucocorticoids
locally and therefore, provide a mechanism for the safe resolution of
inflammation and prevention of secondary neuronal toxicity. Future studies
with 11βHSD-1 null mice in models of neuronal injury could validate these
findings.
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Following LPS challenge, preliminary immunofluorescent analyses
noted a sharp decrease of 11βHSD-1 expression in non-EGFP (possibly
astrocytes and neurons). This would suggest a neuroprotective response
mediated by 11βHSD-1, given neuronal cell’s susceptibility to high
concentrations of glucocorticoids. Therefore, a model can be suggested
where, as systemic or brain inflammation proceeds, 11βHSD-1 expression
allows particular cell types in the brain to adapt and respond to elevated
blood glucocorticoid levels resulting from HPA axis activation. This
includes microglia, which engage in the conversion of inert 11-keto-
glucocorticoids to active 11-hydroxl-glucocorticoids.
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CHAPTER 5
MICROGLIA EXPRESS STEROID-CONVERTING ENZYMES
AND METABOLIZE STEROID PRECURSORS INTO ACTIVE
SEX HORMONES
The brain can synthesize steroids and metabolize circulating hormone
precursors, like DHEA, into active androgens and estrogens. Neurosteroids
have important roles in the homeostasis of the CNS, including
neuroprotection, and their levels correlate negatively with
neurodegeneration. Microglia play a critical role during brain damage
responses, which can be ameliorated by the protective effects of
neurosteroids. The enzymes that catalyze the conversion of cholesterol and
the production of steroid hormones are expressed in the various cell types of
the brain, and although steroid metabolism has been implicated in the brain’s
response to injury, the participation of microglia in this process has not been
described. In view of my findings showing microglia are able to metabolize
adrenal steroids, in this part of my thesis I set out to test the hypothesis that
microglia contribute to the synthesis and metabolism of neurosteroids in the
brain. To do so, I applied the RT-PCR gene expression approach, coupled to
functional assays of steroid conversion for particular enzymes.
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Gene expression of steroid-converting enzymes in microglia
Although the steroid-metabolizing capacity of the principal cells in
the CNS has been described to some extent, there are no reports addressing
the contribution of microglia to brain steroidogenesis. To investigate the
expression of the main steroid-converting enzymes in mouse microglia, I
designed gene specific primers for Real Time PCR (RT-PCR) (Table 1). RT-
PCR analysis of RNA from adult FACS-sorted microglia (ex vivo MG) and
from primary microglia cultures (1°MG) revealed expression of the
following genes: peripheral benzodiazepine receptor (PBR), steroid acute
regulatory protein (StAR), aryl sulfatase (ArsaA), steroid sulfatase (StS) 3β-
hydroxysteroid dehydrogenase type 7 (3βHSD7), 17β-hydroxysteroid
dehydrogenase type 1 (17βHSD1), and 5α-reductase (5αR) (Table 2). On
the other hand, cytochrome p450 side chain cleavage enzyme (p450scc),
cytochrome p450 21-hydroxylase (p450c21), cytochrome p450 17-
hydroxylase (p450c17), DHEA sulfotransferase (Sulft), 3βHSD type 1, 2,
and 4, cytochrome p450aromatase (p450Arom), and 3α-hydroxysteroid
dehydrogenase (3αHSD) were not detected (Table 2). The ratio of specific
gene Ct values to the Ct value of L27A, a housekeeping gene, was calculated
as a way of assessing the relative expression levels of each gene between ex




Thus, the most abundant genes expressed were the PBR (ratio of 0.80;
0.94) and Arsa (ratio of 0.85; 0.83), while the lowest expression was found
for StAR (ratio of 0.68; 0.62) (Table 2). No differences were found between
the expression levels of ex vivo MG and 1°MG (Student T-test; p=0.16-
0.64), except for the PBR (p<0.0001) and 3βHSD7 (p<0.05), which were
expressed at higher levels in 1°MG (Table 2). A summary of the expression
profile of steroid-converting enzymes in microglia is depicted in Fig.24.
LPS stimulation modulates expression of steroid-converting enzymes in
microglia
To analyze the expression of steroid-converting enzymes in activated
microglia, adult cfms-EGFP male mice were injected i.p. with saline or
5mg/kgLPS; 24hr later, brains were extracted and microglia were isolated by
FACS-sorting (Chapter 4). This in vivo stimulation paradigm with LPS leads
to the activation of brain microglia, indicated by changes in morphology and
the expression of pro-inflammatory cytokines (Sierra, Gottfried-Blackmore
et al. 2007; Sierra Submitted). In vivo stimulation with LPS led to an overall
decrease in the expression of steroid-converting enzymes (Fig.25). StAR
expression was decreased by 38.8±9.3% (p<0.05), Arsa by 26±10.6% (not
significant), 3βHSD7 by 64.1±2.9% (p<0.001), 17βHSD1 by 71.4±0.8%
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(p<0.05), and 5αR by 66.6±1.8% (p<0.05) (Fig. 25). One notable exception
was the PBR, whose expression was significantly increased 7.7±2.2-fold
(p<0.05) (Fig.25). Furthermore, LPS stimulation did not induce the
expression of p450scc, p450c21, p450c17, Sulft, 3βHSD1-2,4, p450Arom,
or 3αHSD.
To further explore the effects of other pro-inflammatory stimuli on
steroid-converting enzyme expression, primary microglia cultures (1°MG)
were used. 1°MG were stimulated for 24hr with LPS+INFγ or INFγ alone
and enzyme expression was assessed by RT-PCR. Stimulation with
LPS+INFγ led to an increase in the expression of all the steroid-converting
enzymes that were expressed in resting 1°MG (Fig.26). PBR expression was
increased 9.6±1.0-fold (p<0.01) (Fig.26A), StAR increased 4.5±0.7-fold
(p<0.05) (Fig.26B), Arsa increased 1.9±0.1-fold (p<0.01) (Fig.26C),
3βHSD7 increased 2.9±0.4-fold (p<0.01) (Fig.26D), 17βHSD1 increased
3.3±0.4-fold (p<0.01) (Fig.26E), and 5αR was increased 5.1±0.6-fold
(p<0.01) (Fig.26F). INFγ stimulation alone only affected the expression of
3βHSD7 (increase of 2.9±0.4-fold (p<0.05)) (Fig.26D).
In vivo, i.p. injection of LPS induces high levels of circulating




expression of pro-inflammatory cytokines (Chakravarty and Herkenham
2005; Sierra, Gottfried-Blackmore et al. 2007). Our in vivo experiments with
LPS yielded a down-regulation of steroid-converting enzyme expression. To
determine whether an enriched milieu of inflammatory cytokines could
mimic our in vivo results, 1°MG cultures were stimulated with microglia
LPS-conditioned media, which contains LPS and high levels of several
inflammatory cytokines such as TNFα, IL-6 and NO (Sierra Submitted), as
well as IL1β, IL-12, MCP-1, MCP-5, and RANTES (Chapter 2). This LPS-
conditioned media (LCM) was used to stimulate fresh cultures of 1°MG.
24hr stimulation with LCM did not induce a down-regulation of steroid-
converting enzymes. Instead, it mimicked the LPS+INFγ effect on 1°MG,
but to a lesser extent (Fig.26).
Finally, 24hr stimulation with cAMP, a known inducer of
steroidogenesis in various endocrine cells, had no effect on the expression of
steroidogenic enzymes in 1°MG (Fig.26). None of the treatments in 1°MG
induced the expression of p450scc, p450c21, p450c17, Sulft, 3βHSD1-2,4,
p450Arom, or 3αHSD (data not shown).
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Steroid-converting activity in microglia
The results from our RT-PCR analysis suggested that microglia
express the enzymes required for the conversion of DHEA into androgens
and estrogens (Fig. 24). Steroid-converting activity of microglia was
evaluated by incubating 1°MG with the steroid precursor
dehydroepiandrosterone (DHEA) and measuring its metabolism. H3-DHEA
conversion of steroids was analyzed by thin layer chromatography (TLC)
and beta counting of radioactive metabolites (Fig. 27). After 24hr
incubation, 1°MG showed a 30±3.3% (p<0.0001) conversion of H3-DHEA,
with Adiol being the only product detected of this conversion, accounting
for 15.5±%1.3 (p<0.0001) of H3-radioactivity (Fig.27A). To determine if the
activation of microglia would induce any change in enzyme activity, 1°MG
were stimulated with LPS+INFγ  and co-incubated with H3-DHEA.
Microglia stimulation had no effect on the conversion or profile of steroids
produced from H3-DHEA compared to resting cells (Fig.27B).
In steroidogenic glands, androstenedione (AD) is the main
intermediary product between DHEA and the downstream synthesis of
androgens and estrogens. 1°MG incubated with H3-AD for 24hr showed a




products of its conversion being T, 12.8±0.8% (p<0.0001); 5αAD, 3.8±0.8%
(p<0.01); and DHT, 14.4±3.1% (p<0.01) (Fig.28A). Like in my DHEA
experiments, LPS stimulation of the cells did not affect the conversion or the
profile of steroids produced from H3-AD (Fig.28B).
PBR role in microglia
PBR was the most abundant transcript detected in microglia;
additionally, it showed a robust (7.7 to 9.6 fold) increase following
microglia activation. The absence of cholesterol metabolizing enzymes, i.e.
low levels of StAR and absence of p450scc and p450c17, suggest that PBR
may play an alternate role in microglia. Stimulation of microglia with two
selective ligands for the PBR, Ro and PK (10pM), led to a specific reduction
of LPS-induced production of TNFα (16.2±10.8% decrease (p<0.05), and
40.9±8.9% (p<0.05) respectively), but had no effects on IL-6 and NO
(Fig.29), except a 12.4±6.4% (p<0.05) increase by PK on NO (Fig.29). In
contrast to these modulatory actions on cytokines, PBR ligands did not
affect the metabolism of DHEA or AD (data not shown).
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Adiol is an effective estrogen receptor agonist
The sole product of DHEA metabolism in 1°MG was Adiol. This
steroid has been reported to have androgenic and estrogenic properties
(Poortman, Prenen et al. 1975). To determine whether Adiol could function
as a specific estrogen receptor (ER) agonist, we utilized an ER-expressing
neuronal cell line, EtC.1 (Chapter 6) (Gottfried-Blackmore in preparation),
transfected with a luciferase gene reporter coupled to 3 estrogen response
elements (EREs). Incubation of these cells with Adiol induced the
expression of the luciferase gene reporter at a high dose (1µM), but not at a
lower dose (10nM) (Fig.30). Moreover, this induction was completely
abrogated by pre-treatment of the cells with the specific ER-antagonist ICI-
182,780 (100nM) (Fig.30). Microglia were not used for this assay because of




Given the key role of microglia in neurodegeneration and the
protective effects of neurosteroids, in this section of my thesis I attempted to
verify whether microglia contribute to the synthesis and metabolism of
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steroid hormones in the brain. Neuro-steroidogenesis involves the de novo
synthesis of steroid hormone precursors, such as pregenenolone,
progesterone and DHEA, from cholesterol within the brain. Some
controversy still exists about this process occurring in the brain, mainly from
conflicting results in the expression of p450c17 (Baulieu and Robel 1998;
Zwain and Yen 1999), which yields DHEA. My results reveal that microglia
do not express p450c17 nor p450scc, p450c21, or 3βHSD1-2, and therefore
these cells do not have the capacity to synthesize neurosteroids from
cholesterol.
Alternate roles for Steroidogenic Proteins
In spite of the lack of p450scc and p450c17, microglia expressed low
levels of StAR mRNA, which is the main mediator for cholesterol import to
the mitochondria for the initiation of steroidogenesis (Stocco 2000; Sierra
2004). StAR expression in microglia is likely to be playing a different role in
these cells, such as cytosolic free sterol transfer, as has been suggested for
other cholesterol binding proteins in macrophages (Rodriguez-Agudo, Ren
et al. 2006).
Like StAR, the PBR also participates in the import of cholesterol into
the mitochondria (Hauet, Liu et al. 2002). In the brain, PBR expression is
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increased following nerve injury and can increase steroidogenesis locally
(Lacor, Gandolfo et al. 1999). Aside from its role in steroidogenesis (Brown
and Papadopoulos 2001), the PBR is widely expressed in monocytic cells
(Carayon, Portier et al. 1996), and has been identified as a marker of
activated microglia (Banati 2002). In my experiments with microglia PBR
was the most abundant gene expressed. This is consistent with studies
reporting that PBR is mainly expressed in glial cells, and its expression
levels increase following glial activation induced by inflammation or
neuronal damage [rev. by (Casellas, Galiegue et al. 2002)]. 1°MG and ex
vivo MG challenged with inflammatory stimuli (LPS+INFγ or LPS injection
respectively) responded with an increased expression of PBR.
In spite of enhanced PBR expression, PBR ligand stimulation, which
increases steroidogenesis in other tissues (Lacor, Gandolfo et al. 1999;
Brown and Papadopoulos 2001), had no effect on DHEA or AD conversion
in microglia, probably because these PBR ligands affect the initial import of
cholesterol into the mitochondria providing more substrate for p450scc,
which is lacking in microglia. Yet, PBR ligands selectively decreased the
TNFα response to LPS stimulation in 1°MG, in accordance with previous
reports (Taupin, Gogusev et al. 1993; Taupin, Toulmond et al. 1993; Choi,
Khoo et al. 2002). My data corroborate the proposed immuno-modulatory
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role of PBR, which may account for this protein’s expression in microglia
and its reported neuroprotective effects (Leonelli, Yague et al. 2005; Veiga,
Azcoitia et al. 2005).
LPS Activation and expression of Steroid-converting Enzymes in Microglia
Our results showed a significant reduction in all the steroid-converting
enzymes expressed in ex vivo microglia after i.p. LPS activation. However,
in vitro in primary microglia, LPS+INFγ caused an increase in steroid-
converting enzyme expression. These differences between in vivo effects of
LPS and in vitro could be due to a number of reasons. An argument could be
made for the developmental difference between adult FACS-sorted
microglia and neonatal primary microglia, yet both cell populations showed
similar expression levels of mRNA in the resting state, and when activated
showed similar responses to genes like the PBR and 11βHSD-1 (Chapter 4).
Systemic injection of LPS in vivo causes a rapid induction of
circulating cytokines and inflammatory mediators (Chensue, Terebuh et al.
1991), which can induce pro-inflammatory genes in microglia (Rivest 2003;
Sierra, Gottfried-Blackmore et al. 2007). The down-regulation of steroid-
converting enzyme expression in vivo due to cytokines could be ruled-out as
well, given that in vitro, single cytokine stimulation (INFγ) or stimulation
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with a combination of cytokines (LPS-conditioned media) showed only
marginal effects. A caveat of these experiments is that the cytokines from
microglia LPS-conditioned media may not mimic the cytokine milieu in the
brain after i.p. LPS injections.
My results would suggest that other factors in vivo may be causing the
down-regulation of steroid-converting enzymes in microglia, such as
glucocorticoids. Following the systemic rise of cytokines, activation of the
hypothalamic-pituary-adrenal (HPA) axis causes a 3-4 fold increase in
circulating glucocorticoid levels (rev. by (Besedovsky and del Rey 1996)),
which can block steroidogenesis in testicular Leydig cells (Gao, Shan et al.
1996; Badrinarayanan, Rengarajan et al. 2006). Similar effects of
glucocorticoids may be occurring in brain microglia. Preliminary
experiments indicate that corticosterone incubation can inhibit H3-DHEA
conversion in 1°MG (Fig.31). The effects of corticosterone on the
expression of steroid-converting enzymes in microglia should be addressed
in future studies.
In spite of the LPS-induced mRNA regulation of steroid converting
enzymes, LPS+INFγ stimulation of 1°MG did not affect the rate or
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metabolism of H3-DHEA or H3-AD. These results are similar to what I
found with 11βHSD-1 activity. Additional cofactors, such as NADP, may be
required for observing effects of LPS treatment on actual steroid metabolism
(Chapter 4).
DHEA metabolism and formation of active estrogens and androgens by
microglia
In the CNS, DHEA has multiple effects reminiscent of sex hormones
(Majewska 1995). The absence of a specific receptor for this hormone
(Regelson and Kalimi 1994) has led investigators to suggest that DHEA is
metabolized into active sex hormones that mediate the observed effects
(Schmidt, Kreutz et al. 2000; Jellinck, Croft et al. 2005; Jellinck Submitted).
Neurons, astrocytes and oligodendrocytes can metabolize DHEA into sex
hormones (Zwain and Yen 1999). Recently, in collaboration with Dr.
Jellinck (Queen’s University, Canada), we reported that the microglial cell
line, BV2, is able to convert DHEA into Adiol and validated the identity of
this product by high-performance liquid chromatography (Jellinck In press).
My current study corroborates these findings in 1°MG and shows the
expression of 17βHSD1, required for this conversion, both in ex vivo MG
and 1°MG.
112
In humans, DHEA levels are higher in brain than in circulation and
have been correlated with aging and neurodegeneration (Weill-Engerer,
David et al. 2002). Moreover, DHEA conversion in the brain into
metabolites like Adiol may be reduced in patients with neurodegenerative
disease (Weill-Engerer, David et al. 2003). Our data indicate that microglia
can metabolize DHEA and specifically convert it to Adiol. This delta-5
steroid has reported androgenic and estrogenic properties in peripheral
tissues (Poortman, Prenen et al. 1975; Adams 1985; Miyamoto, Yeh et al.
1998). Additionally, early studies describe Adiol binding pituitary estrogen
receptors in the male rat brain and exerting estrogenic effects (Thieulant,
Benie et al. 1983). Here I present evidence confirming that Adiol is an
effective estrogen receptor agonist in ER-expressing neuronal cells (EtC.1).
These data suggest that DHEA metabolism by microglia may be a source of
active estrogens in the brain.
The results presented in this chapter indicate that microglia, like the
other cells in the CNS, participate in the metabolism of steroid hormones
through the expression and activity of steroid converting enzymes. Microglia
do not participate in the initial utilization of cholesterol for generation of
steroid hormone precursors, but rather show active metabolism of DHEA
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and AD. The steroid converting capacity of microglia may be regulated by
inflammatory stimuli, yet other factors need to be considered when
performing in vitro studies. DHEA metabolism in microglia showed the
exclusive formation of Adiol, which may function as a source of active
estrogens in the brain.
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CHAPTER 6
EFFECTS OF ESTROGEN ON CELLS FROM THE DEVELOPING
CNS: EtC.1
E2 effects on microglia are marginal at best, compared to
glucocorticoids, as indicated by my results (Chapter 3). However, further
studies indicated that microglia may contribute to the formation of active
estrogens (Chapter 5), which positively impact neuronal cells. Neurons are
profoundly affected by estrogen, even in brain areas that are not related to
reproductive functions (Priest and Pfaff 1995; McEwen, Alves et al. 1997;
McEwen 2001). Most neuronal cells studied so far exhibit responses to
estrogen that include modulation of their synaptic inputs (Woolley and
McEwen 1992; Lewis, McEwen et al. 1995; Woolley, Weiland et al. 1997;
Leranth, Hajszan et al. 2004), a higher resistance threshold to physiological
stressors [rev. by (Behl 2002)], the ability to resist cell death or induction of
apoptosis [rev. by (Amantea, Russo et al. 2005; Suzuki, Brown et al. 2006)],
and even effects on neurogenesis and neuronal differentiation/maturation
(Tanapat, Hastings et al. 1999; Brannvall, Korhonen et al. 2002; Kishi,
Takahashi et al. 2005). However, the extent of E2’s non-reproductive effects
in the developing CNS is less well understood. As part of the laboratory’s
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efforts to further our understanding of estrogen’s neurotrophic effects, and to
investigate estrogen’s effects on developing neurons, I undertook parallel
studies to characterize a neuronal cell line from developing mouse brain
cerebellum, EtC.1, and evaluate its responsiveness to estrogen. Additionally,
throughout my studies with estrogen and microglia, I used elements of this
neuronal system as a positive control of estrogen’s effectiveness in my cell
culture systems.
Characterization of the EtC.1 Cell line
Development of the mouse cerebellum occurs at a late embryonic
stage and continues through the first few weeks of postnatal life.  The EtC.1
cell line was originally cloned from embryonic mouse brain cerebellum and
judged to be neuronal on the basis of its electrical excitability and
characteristic surface antigens (Bulloch, Stallcup et al. 1977; Bulloch,
Stallcup et al. 1978). The cells respond positively in a sodium flux assay that
correlates well with the ability to generate action potentials, and also express
one or more of three antigens previously found to be specific for nerve cells
(Bulloch, Stallcup et al. 1977).
In the present study the EtC.1 cells were examined and analyzed for
the expression of proteins commonly expressed in neural stem cells and
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progenitor cells. This study was carried out jointly with Gist Croft M.S., a
former research assistant in the laboratory. Additionally, the expression of
specific cerebellar transcription factors was evaluated to determine the
lineage and developmental stage of EtC.1 cells. These experiments were
necessary for determining if the EtC.1 cell line could serve as a model for
studying estrogen effects on developing cerebellar neurons.
EtC.1 cells were positive for the neuronal stem cell markers Nestin,
Vimentin, Doublecortin (DCX), and Musashi (Fig.32A). However, EtC.1
were negative for the astrocyte marker GFAP, (Fig.32A), but expressed the
neuronal marker NeuN (Fig.32B). These results confirm the early
characterizations of the EtC.1 cells and substantiate their early
developmental stage (Gottfried-Blackmore in preparation).
The developing cerebellum contains primarily progenitor cells of two
principal lineages: the granule cell lineage and the Purkinje cell lineage. To
distinguish to which lineage of cells the EtC.1 belong to, expression of
lineage specific markers was performed by PCR. Zipro1, a defining
transcription factor for the granule cell lineage (Yang, Zhong et al. 1996)
was expressed in EtC.1 cells, as well as the granule cell precursor
transcription factor Math-1 (Ben-Arie, Bellen et al. 1997), Pax-6




at low levels (Fig. 33). In contrast, Calbindin, a commonly expressed marker
in Purkinje cells, was not expressed in EtC.1 (Fig.33). In agreement with the
precursor phenotype of the cells, Zic-1 and Zic-2, two transcription factors
expressed in mature cerebellar granule cells (Aruga, Minowa et al. 1998;
Aruga, Inoue et al. 2002), were not expressed in EtC.1 (data not shown),
whereas the Cyclin-D2 gene present in dividing neural progenitor cells
(Ross, Carter et al. 1996) was expressed (Fig.33).
Characterization of E2 receptors expressed in EtC.1 cells
Although estrogen receptors have been identified within the adult
cerebellum (Litteria 1987; Jakab, Wong et al. 2001; Mitra, Hoskin et al.
2003), and during development (Belcher 1999; Price and Handa 2000; Guo,
Su et al. 2001; Ikeda and Nagai 2006), the role of estrogen (E2) in the
development of cerebellar neurons and their function in the adult has yet to
be fully elucidated. Reminiscent of the effect seen on the principal cells of
the adult mouse and rat hippocampus (Woolley and McEwen 1992), E2 is
reported to affect the growth of dendritic spines in developing cerebellar
Purkinje cells (Sakamoto, Mezaki et al. 2003).
Expression and function of ERs in EtC.1 was first assessed by WB
analysis with specific antibodies against ERα and ERβ. ERα staining
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demonstrated an expected band (67 kDa) for EtC.1 protein extracts, which
matched recombinant human ERα transiently expressed in EtC.1 (Fig.34A).
ERβ staining yielded three bands (20kDa 45kDa and 100kDa) for EtC.1
protein samples; these did not match bands from mouse control tissues
(ovary and prostate), nor from the human recombinant ERβ band (54kDa)
(Fig.34B). Given some of the controversy that surrounds estrogen receptor
antibodies, expression of ERα and ERβ transcripts was analyzed by qRT-
PCR. Both ERα and ERβ transcripts were found in EtC.1. Additionally,
ERα, but not ERβ, mRNA levels were reduced after E2 incubation (data not
shown). These results indicate the predominant expression of ERα in EtC.1
cells.
The transcriptional activity of ERα and ERβ in the EtC.1 cell line was
assessed in cells transiently transfected with an ERE-luciferase reporter gene
construct. In this system, the detection of enzymatic luciferase activity in
cell lysates is an indirect measure of transcription induced by activated ERs.
After transfection, unstimulated cells showed minimal luciferase activity,
while a physiological dose (10nM) of exogenous E2 induced a ca. 80-fold
response over basal transcription (Fig.35). Luciferase induction reached a
maximum at 12hr of E2 incubation and remained high at 24hr (data not
shown). Subsequent experiments were performed using the 24hr time point.
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E2-induction of reporter gene transcription was blocked by the ER
antagonist ICI 182,780 (ICI) in a dose-dependent manner (Fig.35). ICI alone
had no effect on reporter gene activity (data not shown). Together, these
results show that EtC.1 cells express functionally active ERs.
To distinguish the participation of ERα and ERβ  in the response
elicited by E2, selective agonists for these receptors were compared, namely
the ERα agonist PPT and the ERβ agonist DPN (Tocris). This work was
jointly done with M.S. Croft. Incubation of the cells with the same dose
(10nM) of E2 or the selective ER agonists revealed that the ERα-selective
agonist PPT was significantly less active than E2, and that the ERβ-selective
agonist DPN did not induce luciferase activity (E2 100%; PPT 46±5.7%
p<0.05; DPN 1.2±0.6; p<0.05) (Fig.36A). These results were verified using
a different set of ER agonists, MC1 for ERα and MC2 for ERβ (Merck) (E2
100%; MC1 62±2.16% p<0.05; MC2 2.4±0.44%; p<0.05) (Fig.36B). ERα
and ERβ agonists were not additive, nor did they differ from the induction
levels obtained from PPT alone (Fig.36). Like E2, both ERα-selective
agonists PPT and MC1 were significantly blocked by ICI (Fig.36 p<0.05).
The results suggest that ERβ is not functionally expressed, whereas ERα is
the predominant receptor for E2 in EtC.1 cells.
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Estrogen is known to activate important second messenger signaling
pathways in neuronal cells, such as those mediated by CREB and ERK1/2
MAPK (Lee and McEwen 2001; Lee, Campomanes et al. 2004). To
determine if E2 activated these pathways in EtC.1 cells, serum-starved EtC.1
cultures were stimulated with E2 (10nM) and phosphorylation of CREB and
ERK1/2 MAPK was assessed by WB.  Both MAPK were constitutively
phosphorylated, yet serum-starvation reduced phosphorylation levels (data
not shown). ERK1/2 phosphorylation was induced by fetal calf serum (FCS)
stimulation, but not by E2 treatment (Fig.37A). CREB phosphorylation was
induced by cAMP (1uM), yet was also not affected by E2 treatment
(Fig.37b), indicating that ERs in the EtC.1 did not engage in these second
messenger signaling pathways.
E2 does not affect maturation or development of EtC.1 cells alone
The cerebellum is rich in the expression of ERα and ERβ throughout
development, where the ratio of these receptor subtypes changes as the
cerebellum matures: ERβ seems to have a low constitutive expression in
early development and becomes the predominant receptor in adulthood,
where as ERα appears to play a role mostly in development (Belcher 1999;
Price and Handa 2000; Guo, Su et al. 2001; Ikeda and Nagai 2006).
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Our results showing the predominant expression of ERα in EtC.1 cells are
consistent with this model.
To evaluate if estrogen plays a role in the maturation or differentiation
of EtC.1, cells were incubated for 24hrs and 36hrs with E2 (10nM) and
expression of the various neural and granule progenitor-cell markers was
measured. E2 treatment had no effect on protein levels for the neural
progenitor cell markers analyzed (Nestin, DCX, NeuN, Vimentin, Musashi),
nor was the expression of GFAP induced (data not shown). Further, estrogen
(10nM, 24hrs) did not affect expression levels of Pax-6 or Zipro1.
Additionally, E2 treatment did not induce expression of Zic-1 and Zic-2
(data not shown). These results indicate that estrogen alone is not sufficient
for the differentiation of the EtC.1 phenotype.
In our screen of neural proteins that might be regulated by E2, we
found that EtC.1 cells expressed the fragile-X mental retardation protein
(FMRP) (Fig.38A), which is involved in dendritic spine maturation (Feng,
Gutekunst et al. 1997; Lu, Wang et al. 2004). Moreover, E2 treatment
increased its expression (Fig.38B). To determine if E2 treatment could
induce maturation of synaptic structures in EtC.1 cells, the expression of
various pre- and post-synaptic proteins was assessed by Western blot.
Resting EtC.1 cells were negative for Synaptophysin, Syntaxin, PSD-95,
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Spinophylin, and connexin-36. Further, 24hrs incubation with E2 (10nM)
failed to induce expression of these proteins (Fig.38C). These data indicate
that estrogen alone is not sufficient for the maturation of EtC.1 cells.
Discussion
EtC.1 cells expressed various protein markers characteristic of
neuronal progenitor cells such as Nestin, Vimentin, DCX, and Musashi,
which confirm their early developmental origin. Additionally, EtC.1 cells
were identified as belonging to the granule cell lineage by their expression
of Zipro1, Math1 and En-2, and the absence of the Purkinje cell marker
Calbindin. To our knowledge, this would establish the EtC.1 cell line as the
first available cell line of developing cerebellar granule cells. Further study
of these cells could therefore, contribute to studies aimed at examining
cerebellar granule cell development or maturation.
EtC.1 cells were positive for the expression of ERα and ERβ at the
mRNA level, but at the protein level, expression of ERβ was inconclusive.
Using an estrogen-sensitive gene reporter assay, I determined the function of
these putative receptors. ERα , but not ERβ , was able to drive gene
expression in EtC.1 cells. The expression of functional ERα, but not ERβ, in
EtC.1 cells is in agreement with previous findings demonstrating the
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predominant expression of ERα in the developing cerebellum (Belcher
1999; Price and Handa 2000; Guo, Su et al. 2001; Ikeda and Nagai 2006).
Despite the presence of functional ERα, our findings that estrogen
stimulation alone was not sufficient to induce the differentiation (change in
neural progenitor markers) or maturation (induction of synaptic proteins) of
EtC.1 cells under the conditions tested. This developmental stage of EtC.1
cells may account for their inability to engage ERK1/2 MAPK and CREB
signaling after E2 stimulations. EtC.1 cells may require established signals
to differentiate, such as bone morphogenic proteins (Angley, Kumar et al.
2003), and it may be likely that E2 could synergize with such differentiation
factors or affect their actions. This line of experiments merits further
attention and may be fruitful in future studies.
Using the ERE-Luciferase assay system in EtC.1 cells, I was able to
test the effects of steroids metabolized by microglia, such as Adiol (Chapter
5). In addition, my experiments with microglia and EtC.1 utilized the same
hormone stocks, providing an internal control for the quality of my reagents.
E Rα  expression in EtC.1 provides a model to further study the
neuroprotective effects of E2 in developing granule cells. A model could be
set-up in which microglia derived Adiol and E2 could be compared for their
neuroprotective, or other, properties in these cells.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
Since the initial anatomic description of microglia in the first decade
of the 20th century, and up until the 1980s, these cells were considered as
mere by-standers in the steady state central nervous system (CNS), with a
definite role in development, and proliferative and phagocytic capacity
following brain injuries in the adult. However, our appreciation and
understanding of microglia cells and their roles in brain homeostasis is
steadily increasing. Today microglia are regarded as the main resident
immune cells of the CNS, distinct from peripheral macrophages and
monocytes, with key roles in the initiation and maintenance of inflammatory
responses in the brain [rev in Chapter 1].
Microglia, once activated, become highly pro-inflammatory cells
through their production of cytokines, chemokines, prostaglandins, and free
radicals. Activated microglia exert beneficial effects following injury or an
immune challenge, yet disregulation of the microglial response can be
deleterious (Block, Zecca et al. 2007). Over-activated microglia have been
implicated in basically all forms of neurodegenerative diseases due to the
high susceptibility of neuronal cells to pro-inflammatory mediators, mainly
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free radicals and TNFα [rev in Chapter 1]. Microglial involvement in
neurodegeneration has given this cell type a new status in neuroscience
research.
Given that the over-activation of microglia results in deleterious and
neurotoxic effects, a considerable interest lies in determining whether
activated microglia can be harnessed as effective targets of anti-
inflammatory therapies in the treatment of neurodegenerative disease. The
work presented in this thesis addresses this issue, and elucidates some of the
regulatory processes involved in microglia activation with a focus on anti-
inflammatory steroid hormones.
Clinical and animal studies have pointed to the neuroprotective and
anti-inflammatory effects of steroid hormones [rev in Chapter 1]. The ample
and varied literature on the effects of steroid hormones on inflammation
indicates that diverse factors such as dose, timing and duration of exposure,
receptor subtype and cell-type specific expression, can cause steroids to
exert stimulatory, permissive, or inhibitory actions (Sternberg 2001; Dinkel,
Ogle et al. 2002; Yeager, Guyre et al. 2004; Sorrells and Sapolsky 2007).
Yet our comprehension of these issues is not complete, and in the case of the
CNS, the cellular targets and mechanisms of action of these hormones are
still unresolved. In view of these limitations, the main question addressed in
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this dissertation was the role that microglia play in the well-documented
anti-inflammatory effects of steroid hormones in the brain, with particular
emphasis on the neuroprotective sex hormone 17β-estradiol (E2), and the
anti-inflammatory adrenal steroid, corticosterone.
Steroid hormones and microglia activation
My studies clearly indicate that E2 does not have any profound effects
on the LPS activation of microglia. These results are inconsistent with many
published studies showing that E2 has an anti-inflammatory effect on
microglia. However, on close examination of the literature, one can note that
the field of E2 studies on microglia is riddled with contradictory reports,
(Chapter 1, 3). These contradictions could be accounted by factors such as
the use of microglia cell lines (Bruce-Keller, Keeling et al. 2000; Bruce-
Keller, Barger et al. 2001; Baker, Brautigam et al. 2004), reports comparing
macrophage cell lines to microglia cells (Vegeto, Ghisletti et al. 2004;
Vegeto, Belcredito et al. 2006), species differences between rat and mouse-
derived microglia (Drew and Chavis 2000; Vegeto, Bonincontro et al. 2001;
Sierra Submitted), and the extrapolation of E2 anti-inflammatory effects in
vivo on microglia (Vegeto, Belcredito et al. 2003; Vegeto, Belcredito et al.
2006). As described in this thesis, the absence of ERβ expression and low
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levels of ERα in vivo in mouse microglia, coupled with the failure of E2 to
regulate LPS-induced cytokines or MAPK activation in primary microglia
cultures are strongly suggestive that E2 does not act directly on stimulated
microglia (Chapter 3). Consistent with this data, we found a down-regulation
of ERα mRNA in activated microglia from i.p. LPS-injected mice (Chapter
3).
Despite the claims of positive E2 effects on the pro-inflammatory
state of microglia, my results do correspond with a lesser number of reports
indicating no direct effects of this hormone on microglia activation (Chapter
1,3). However, it is likely that the literature does not reflect all the studies
where no effects of E2 on inflammatory microglia have been found, given
that negative results are often not published (based on private
communications with at least three other laboratories during the annual,
international, Society for Neuroscience Meetings 2004-2006).
These reports and the work presented here suggest a model whereby
other cell types in the brain, such as oligodendrocytes, astrocytes and
neurons, mediate most of E2’s neuroprotective and anti-inflammatory effects
(Fig.39). For example, NF-κB activation in astrocytes has recently been
found to be a key regulator of inflammation in the CNS, and its inhibition
has beneficial effects on tissue regeneration [rev by (Farina, Aloisi et al.
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2007)]. ERs, which are expressed in astrocytes (Azcoitia, Sierra et al. 1999;
Garcia-Ovejero, Veiga et al. 2002), could interfere with NFκB activation
(Wen, Yang et al. 2004). Further, the anti-inflammatory effects of E2 could
be due to indirect events that impact microglial responses, such as effects on
astrocytes and neurons. Examples of these are the E2-induction of anti-
inflammatory and neuroprotective cytokines like TGFβ by astrocytes (Wyss-
Coray, Lin et al. 2001; Sortino, Chisari et al. 2004); and increased
oligodendrocyte (Takao, Flint et al. 2004) and neuronal survival [rev. by
(Behl 2002)] (Fig. 39). Another key mechanism of the anti-inflammatory
effects of E2 in the brain may be the ability of E2 to abolish the autologous
down-regulation of glucocorticoid receptors in the brain (Ferrini, Lima et al.
1995). Taken together, it is likely that the anti-inflammatory and
neuroprotective effects of E2 are separate and complementary actions. A
useful application of this distinction could be the combination of E2 with
well-established anti-inflammatory drugs for future therapies in
neurodegenerative diseases. An example of this approach is reported for
lesioned retinal ganglion cells, where both neuroprotection and regeneration
were enhanced by the combination of two compounds acting on different
sites: a specific drug, aurintricarboxylic acid, acting directly on the neurons,
and cortisol acting on the glial environment (Heiduschka and Thanos 2006).
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Using glucocorticoids as well-established anti-inflammatory
compounds, I found that the adrenal steroid, corticosterone was an effective
regulator of LPS-induced responses in microglia (Chapter 3,4), which is in
agreement with previous reports. The work provided in this thesis supports
the anti-inflammatory effects of elevated concentrations of glucocorticoids
on microglial cells. However, glucocorticoids can act as a double-edged
sword in the CNS, given that prolonged exposure to elevated glucocorticoid
levels is neurotoxic (Sapolsky 1996), and that low levels of glucocorticoids
are pro-inflammatory [rev by (Sorrells and Sapolsky 2007)].
The glucocorticoid receptor mediates most of the known anti-
inflammatory effects of glucocorticoids, yet the mineralocorticoid receptor,
which has a much higher affinity for corticosterone, is reported to have
down-stream pro-inflammatory activity (Tanaka, Fujita et al. 1997). It has
been postulated that early in the inflammatory response, initial low levels of
corticosterone promote inflammation through the high-affinity
mineralocorticoid receptor and unknown glucocorticoid receptor
mechanisms, and then as glucocorticoid levels rise to supra-physiological
levels they mediate anti-inflammatory effects predominantly through
glucocorticoid receptor (Sorrells and Sapolsky 2007). Although the effects
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of mineralocorticoids were not examined in this thesis, our studies indicate
the expression of mineralocorticoid receptor mRNA in microglia (Sierra
Submitted) suggesting that sub-nanomolar concentrations of corticosterone
might be pro-inflammatory (Tanaka, Fujita et al. 1997). The pro-
inflammatory role of the mineralocorticoid receptor in microglia needs
further investigation, and could be a potentially interesting therapeutic
target.
Glucocorticoids are the body’s most effective regulators of
inflammation, exerting permissive, stimulatory, and suppressive effects [rev
by (Sorrells and Sapolsky 2007)]. In this dissertation I present evidence
showing that microglia are not only responsive to glucocorticoids (Chapter
3), but also have the capacity of re-activating inactive glucocorticoids
through 11βHSD-1 expression (Chapter 4). 11βHSD-1 converts 11-DH-Cort
into active corticosterone, thus re-activating glucocorticoids. The local
amplification of glucocorticoids through microglia 11βHSD-1 activity may
be significant, particularly in the context of inflammation, as LPS-
stimulation induced a robust increase of 11βHSD-1 expression in microglia,
both ex vivo and in vitro. These results are suggestive of a model whereby
following a systemic inflammatory challenge, and subsequent production of
glucocorticoids by HPA-axis activation, microglia increase expression of
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11βHSD-1 to amplify the anti-inflammatory effects of corticosterone, which
regulates production of potentially neurotoxic cytokines and free radicals. It
is interesting that in this setting, astrocytes down-regulated 11βHSD-1
expression, indicated by preliminary in vivo immunofluorescence analyses
(Chapter4). This could be considered a protective response given the
neuronal susceptibility to high concentrations of glucocorticoids (Sapolsky
1996).
It has been proposed that 11βHSD-1 expression in the brain plays
roles in cognitive behavior, neuroprotection, and contributes to the negative
feedback of glucocorticoids on HPA activity [rev by (Holmes, Yau et al.
2003)]. 11βHSD-1 activity during brain inflammation is an untapped area of
research. The results I present in this thesis point to an active role of
11βHSD-1, expressed in microglia, in the re-activation of glucocorticoids.
The existence of viable 11βHSD-1 KO mice could serve as a valuable model
to study the participation of this enzyme following neuronal injury and
microglia activation. Additionally, in vivo studies with selective 11βHSD-1
inhibitors could also be fruitful.
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Brain steroid metabolism and microglia
In this thesis I present data that indicates an active role for microglia
in the conversion of active steroids in the CNS (Chapters 4,5). Steroid
hormones play numerous roles in maintaining the homeostasis of the CNS
(Chapter 1). It is intriguing that the brain, like other tissues of the body, has
evolved and acquired the capacity to metabolize and, in some cases,
synthesize these hormones. Furthermore, it’s been postulated that the
appearance of steroid converting enzymes occurred concomitantly with the
appearance of steroid hormone receptors to provide specificity and
regulatory mechanisms as organs became more complex (Baker 2004).
Intracrine production of hormones, that is synthesis or conversion of
hormones within the target cell or tissue (Labrie 1991; Labrie, Luu-The et al.
2005), provides the brain with basal levels of steroids, which have already
proven to play important roles in processes such as nerve regeneration,
synaptic transmission, and notably responses to CNS injury (Chapter 1,5).
Up until now, no reports have described whether microglia participate
in the metabolism of steroids in the brain. The conversion of glucocorticoids
by microglia spurred me to characterize the participation of microglia in the
broader metabolism of brain steroid hormones. In this dissertation I offer
data suggestive of an active role for microglia in the conversion of steroids
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in the CNS (Chapters 4,5). Microglia express steroid-converting enzymes,
which mediated the conversion of steroid precursors DHEA and AD into
downstream hormones. Therefore, microglia may contribute to the pool of
active steroid hormones in the brain, as shown by the production of Adiol,
an active estrogen in neuronal cells (Chapter 5).
It is unlikely that microglia are only causing deleterious effects to the
injured CNS. In fact, it is becoming more widely accepted that microglial
activation is necessary and crucial for host defense and neuronal survival
[rev by (Block, Zecca et al. 2007)]. As proposed for 11βHSD-1 mediated
amplification of anti-inflammatory effects of glucocorticoids, the steroid-
converting capacity of microglia may be particularly significant during
inflammation. Locally, astrocytic steroid metabolism is inhibited by
inflammatory cytokines (Zwain and Yen 1999), whereas in my studies
microglia steroid-converting activity occurred in spite of their activation
state in vitro (Chapter 5). Although my studies also showed a down-
regulation of mRNA expression in ex vivo microglia from i.p. LPS-injected
mice, it remains to be determined what factors caused this down-regulation,
and whether this would also be observed in the setting of a model of
neuronal damage. Androgen production, particularly testosterone, from
DHEA metabolism in microglia may be a substrate for astrocytic and
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neuronal p450 Arom, which synthesizes E2 required for neuroprotection in
various models of neuronal injury (Sierra, Azcoitia et al. 2003; Veiga,
Garcia-Segura et al. 2003; Veiga, Azcoitia et al. 2005).
Inflammation is also known to suppress sex hormone production by
interfering with neuroendocrine gonadal signaling. Within the brain,
cytokines produced by microglia, like IL-2, IL-6, TNFα and IFNγ, affect the
release of anterior pituitary hormones and block the hypothalamic-pituitary
gonadal (HPG) axis (Jones and Kennedy 1993). Systemically, circulating
cytokines can also disrupt HPG axis (Kalra, Fuentes et al. 1990). In addition
to blocking the HPG-axis, inflammatory cytokines directly block
steroidogenesis in the gonads. Macrophage secreted products, such as TNFα
(Andreani, Payne et al. 1991; Xiong and Hales 1997), IL1β (Hurwitz, Payne
et al. 1991) and NO (Pomerantz and Pitelka 1998), can inhibit production of
DHEA and androgens in the testes via inhibition of p450c17 gene expression
(Hales 1992; Li, Youngblood et al. 1995; Onami, Matsuyama et al. 1996). In
contrast to the gonads, adrenal steroid synthesis is increased in response to
inflammation (Chapter 1, 4). Therefore, after an inflammatory challenge or
neuronal injury, DHEA originating from the adrenals could serve as a
substrate for brain steroid conversion in cells like microglia and astrocytes in
the absence of gonadal steroid production (Figure 40).
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Microglia, friend or foe?
In spite of our increased understanding, there are many questions in
microglial biology that remain un-answered, particularly the role of
microglia in the steady-state brain. Classically, ramified or resting microglia
were considered to be inactive under physiological conditions, however, it is
now known that microglia exhibit pinocytic activity and localized motility
(Booth and Thomas 1991; Glenn, Booth et al. 1991). Recent studies have
also shown that resting microglia are engaged in active surveillance of the
brain tissue through their highly ramified protrusions, scanning the entire
brain parenchyma every few hours (Davalos, Grutzendler et al. 2005;
Nimmerjahn, Kirchhoff et al. 2005). Microglial processes directly contact
neuronal cell bodies, astrocytes and blood vessels (Nimmerjahn, Kirchhoff
et al. 2005), therefore it seems likely that microglia monitor the well-being
of brain cells and also function to clear the extracellular milieu to maintain
tissue homeostasis (Booth and Thomas 1991; Thomas 1992; Fetler and
Amigorena 2005). Determining the effects of physiological concentrations
of glucocorticoids on microglial surveillance or chemotaxis may help
unravel more of microglia’s “house-keeping” functions in the CNS.
Another question that remains unclear is: what are the differences
between microglia populations in different brain regions? A great
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heterogeneity of ramified microglia morphologies in different brain regions
has been reported, which suggests that microglia may adapt to distinct
micro-environments (Lawson, Perry et al. 1990). However, it is unknown
whether this morphological variability reflects functional differences. One
potential and appealing difference may be microglial responses to
inflammatory stimuli or their receptivity to steroid hormones.
During CNS injury or pathology, it is still unclear to what extent
resident microglia versus newly recruited cells from the bone marrow
contribute to the resolution or the augmentation of neuronal cell death. In
transgenic mouse models of Alzheimer’s disease, it has been reported that
blood-derived microglia and not their resident counterparts have the ability
to eliminate β-amyloid deposits by a cell-specific phagocytic mechanism
(Simard, Soulet et al. 2006). Additionally, impairing the accumulation of
blood-recruited microglia at sites of plaque deposition causes increased β-
amyloid load and leads to premature death (Khoury, Toft et al. 2007).
However, β-amyloid is pro-inflammatory and activates microglia to release
neurotoxic factors such as NO, TNFα, and superoxide, which potentiates
neuronal damage and symptoms in Alzheimer’s patients [rev by (Block,
Zecca et al. 2007)]. It is likely that these neurotoxic effects are mediated by
both resident and incoming microglia (Moore, El Khoury et al. 2002). Anti-
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inflammatory drugs, like glucocorticoids, may be useful in slowing the
progression of Alzheimer's disease (AD) through their effects on microglia
activation. However, large-scale studies with anti-inflammatory drugs have
produced negative results (Aisen 2002). Better understanding of the anti-
inflammatory effects of E2 and glucocorticoids may result in beneficial
therapies for progressive neurodegenerative diseases.
The conditions defining whether microglial activation is detrimental
or beneficial to neuronal survival are still poorly understood. However, it is
becoming more widely accepted that although microglial activation is
necessary and crucial for host defense and neuron survival, the over-
activation of microglia results in deleterious and neurotoxic consequences
[rev by (Block, Zecca et al. 2007)]. A better understanding of the conditions
regulating this cell type’s activation will definitely lead to improved
therapeutic approaches for neurodegenerative diseases.
Based on the work presented in this thesis, I propose that activation of
microglia by innate immune pathways, such as LPS stimulation, is
predominantly regulated by glucocorticoids, rather than E2. Under this
model, microglia serve as key mediators of the anti-inflammatory effects of
adrenal steroids, whereas the effects of E2 are mediated through other glial
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cells and neurons. Additionally, microglia can be considered active
contributors to the steroid-converting capacity of the brain; On one hand,
amplifying the local anti-inflammatory effects of glucocorticoids in an
autocrine manner, and on the other, potentially providing active androgens
and estrogens that can affect neurons and astrocytes in view of non
demonstrable effects of E2 on activated microglia and the absence of
androgen receptors, ERβ, and low levels of ERα. Future studies aimed at
elucidating the autocrine and paracrine anti-inflammatory and
neuroprotective roles of microglia-derived steroids during CNS
inflammatory responses to injury are promising and merit consideration.
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MATERIALS AND METHODS
In vitro Culture (BV-2 microglia, 1°MG and EtC.1 cells)
BV-2 microglia cultures: Cells from an early passage (#3) were
cryopreserved in liquid nitrogen according to standard tissue culture
protocols. Cryoprotected cells were quickly thawed and seeded in 20 ml of
Dulbecco’s Modified Eagle Media with 4mM glutamine (DMEM, Gibco,
Carlsbad, CA) containing 20% heat-inactivated Fetal Calf Serum (FCS)
(Sigma, St. Louis, MO) and Penicillin, Streptomycin, Antimycotic (PSA)
(Gibco). Cells were cultured in 75cm2 tissue culture flasks (BD, Franklin
Lakes, NJ) in a CO2 water jacketed incubator at 37ºC with 5% CO2.  After
initial plating, confluent cultures were trypsinized (0.25%, trypsin, Gibco),
centrifuged, and re-suspended in standard culture media (SCM) comprised
of DMEM containing 10% fetal calf serum plus PSA. All cells used in these
experiments were derived from passages 4-10. The properties evaluated in
this study remained stable throughout all passages. Tissue culture
microscopy was performed with a Nikon inverted fluorescent microscope
(Nikon, Melville, NY).
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Primary microglia (1°MG) cultures: Microglia cultures were prepared
following standard protocols (23). Briefly, day 2-old mouse pup brains were
dissected on ice, and the meninges were carefully removed. The forebrains
were minced in 5% FCS-PBS buffer, dissociated using fire polished Pasteur
pipettes, and then passed through a 40µM nylon cell strainer (BD). Cells
were washed once in buffer and seeded in culture media (10% FCS DMEM
+ PSA) at a density of roughly two forebrains per 75mm flask. Cells were
grown at 37°C, 5 %CO2, culture media was changed every 5 days, and,
where indicated, supplemented with 5ng/ml macrophage-colony or
granulocyte-monocyte colony stimulating factor (MCSF, Sigma, St. Louis,
MO; or GM-CSF, Cell Sciences, Canton, MA). After 2 weeks in culture
cells were shaken at 125rpm for 5hrs at 37°C to harvest detached microglia.
Microglia were then counted and seeded in 10%FCS DMEM for different
assays; for RNA-PCR: 6-well plates at a density of 1 million cells/well; or
for hormone metabolism-TLC, and cytokine assays: in 24-well assay plates
at a density of 0.25-0.3 million cells/well. After plating, microglia were
allowed to adhere for 1hr and then rinsed with DMEM to remove non-
adherent glial cells. Finally, 10%DMEM ± MCSF or GM-CSF was added to
the cells and left overnight. The following day cells were rinsed with
DMEM and treated as described below.
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Microglia stimulations: For the activation of BV-2 cells, cells were rinsed
and then incubated with 100ng/ml LPS diluted in DMEM alone.  As LPS
requires a specific serum binding protein for effective delivery to its cognate
receptor (Hailman, Lichenstein et al. 1994), the LPS-induction of cytokines
was dependent on media serum concentrations. Therefore, experimental
conditions were adjusted to 1% FCS (1/10th of normal serum levels) for
effective stimulation of the cells. To induce 1°MG activation, cells were
incubated at 37°C with 1%FCS DMEM plus 100ng/ml LPS+ 10ng/ml INFγ.
INFγ was supplemented to LPS to obtain a robust nitric oxide (NO)
response.
LPS+ INFγ conditioned media (LCM) was obtained by stimulating
1°MG cultures with 1%FCS DMEM plus 100ng/ml LPS+ 10ng/ml INFγ,
collecting the supernatants 24hr later, and centrifuging at 2000rpm for 5min
to clear any debris. LCM contains elevated levels of several inflammatory
cytokines such as TNFα, IL-6 and NO, as well as IL1β, IL-12, MCP-1,
MCP-5, and RANTES (Chapter 2). This LCM was used to stimulate fresh
cultures of 1°MG.
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Estrogen, corticosterone and PBR ligand stimulation: Microglia cultures
were pre-treated for 10 minutes (or other time points, see Chapter 2) in
DMEM with 17β -estradiol (E2), corticosterone (Cort), 11-dehydro-
corticosterone (11-DH-Cort), Ro 5-4864 (Ro) or PK-11195 (PK) (all
compounds from Sigma), before 1%FCS LPS+INFγ stimulation. Stock
solutions of all hormones were made in EtOH and stored at –20C. Final
working dilutions were prepared with DMEM alone. Vehicle (EtOH) was
always used as a control in non-treated cells at the same dilution.
Incubation with tritiated (H3) glucocorticoids: The day after seeding, cells
were rinsed and incubated in 0.25ml DMEM containing 3nM [1,2,6,7H3]-
Corticosterone (70 Ci/mmole) (NEN Life Science Products, Boston, MA) or
2nM [1,2,6,7 H3]-11-dehydro-corticosterone (80 Ci/mmole). [H3]-11-
dehydro-corticosterone was synthesized from [H3]-corticosterone and kindly
provided by the laboratory of Dr. Hardy (Population Council, RU, NY).
Radioactive steroids were incubated for various time points ± 11βHSD
inhibitors, 11-keto-progesterone and 11-OH-progesterone (kind gift of Dr.
Hardy). In experiments with activated microglia, cells were co-incubated
with 100ng/ml LPS+10ng/ml INFγ in 1%FCS DMEM. All incubations were
conducted in a 5% CO2 atmosphere at 37°C. The incubations were stopped
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by collecting the supernatant and vortexing with 2ml of diethyl-ether
(Fisher, Carlsbad, CA). The organic phase extract was isolated and
evaporated to dryness at room temperature, the residue was re-dissolved in
70µl of diethyl-ether, and separated by thin layer chromatography (TLC) for
quantification of each product.
Incubation of tritiated (H3) hormones and steroid extraction: The day after
seeding, cells were rinsed and incubated in 0.2ml DMEM containing
16.7nM [1,2,6,7-H3] DHEA (60 Ci/mmol) or 11nM [1,2,6,7-H3] AD (105
Ci/mmol) (Perkin Elmer Life Science, Shelton, CT) for 22-24hr. All
incubations were conducted in a 5% CO2 atmosphere at 37°C. The reaction
was stopped by vortexing the supernatant with acetone (0.2 ml) and ethyl
acetate (0.5ml) (Fisher). A 0.2 ml portion of the organic phase extract was
evaporated to dryness at room temperature, the residue was re-dissolved in
methanol, and the yield of metabolites was determined after separation by
thin layer chromatography (TLC).
EtC.1 cell culture: The EtC.1 cell line was cloned from embryonic day 17
(E17) mouse brain and tested for its neuronal properties (Bulloch et al.,
1977; Bulloch et al., 1978). Cells from an early passage (#3) were
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cryopreserved in liquid nitrogen for future use, according to standard tissue
culture protocols. Cryoprotected cells were quickly thawed and seeded in 25
ml of DMEM with 4mM glutamine containing 20% heat-inactivated FCS
and PSA in 75cm2 tissue culture flasks in a CO2 water jacketed incubator at
37ºC with 5% CO2.  After initial plating, confluent cultures were
trypsinized, centrifuged, and re-suspended in standard culture media
comprised of DMEM containing 10% FCS plus PSA. All cells used in these
experiments were derived from passages 4-10. The properties evaluated in
this study remained stable throughout all passages.
For experiments with E2 incubations, cells were either serum starved
or cultured in Charcoal Stripped fetal calf serum  (CSS, Hyclone, Logan,
UT), as charcoal stripping removes endogenous bovine hormones and
growth factors that could spuriously influence results. For ERK1/2 and CREB
phosphorylation experiments, cells were serum starved in DMEM without
serum for 12hr and 48hr respectively, before stimulation with E2.
In vivo experiments (cfms-EGFP mice)
Animals: For these studies, the transgenic mouse line p7.2fms-EGFP
(C57BL6/6 X CBA background) was used (Sasmono, Oceandy et al. 2003).
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Enhanced green fluorescent protein (EGFP) expression is driven by the
promoter and the regulatory elements of the c-cfms gene that encodes the
receptor for macrophage colony stimulating factor (CSF-1), resulting in
EGFP expression in cells of the mononuclear phagocytic lineage, including
microglia (Sasmono, Oceandy et al. 2003). The p7.2fms-EGFP mouse line
was generously provided to the lab by Dr. Hume (Queensland, Australia)
and Dr. Pollard (Albert Einstein, NY), and a colony was reared and
maintained in the Rockefeller University Animal Facility for these studies.
Animals were bred under 12:12 ligh:dark cycle and free access to chow and
water. To induce inflammation, male mice received a single intraperitoneal
(i.p.) injection with Salmonella typhimurium lipopolysaccharides (LPS; 1-5
mg/kg; Sigma, L2262). All experimental procedures were approved by the
Rockefeller University Animal Care and Use Committee.
Ex vivo Microglia Isolation by fluorescence activated cell sorting (FACS):
Previously reported methods to obtain a single population of microglia by
FACS were used (Sierra, Gottfried-Blackmore et al. 2007). In brief, adult
mice (2-3 months of age) were anaesthetized with pentobarbital (750mg/kg)
and rapidly decapitated. Brains were removed and placed on ice in Hank’s
balanced salt solution (Gibco, Carlsbad, CA), and meninges, blood vessels
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and choroid plexus were carefully removed under a dissecting scope. Brain
cell suspensions, obtained after incubation with type II-S collagenase (600U;
Sigma) and DNAse (450U; Invitrogen, Carlsbad, CA) for 30min at 37ºC in
15ml HBSS supplemented with 90 mM CaCl2, were homogenized by
repetitive gentle pipetting with fire-polished Pasteur pipettes on ice followed
by filtering through a 40µm cell strainer (BD).
Cells were washed by centrifugation and subject to percoll gradient
centrifugation as described previously (Sierra, Gottfried-Blackmore et al.
2007). Cells collected from the 30/70 interphase, were washed and re-
suspended in 5% FCS (fetal calf serum)-PBS containing 100ng/ml
propidium iodide (PI), before sorting in a FACS Vantage SE Flow
Cytometer (BD, Rockefeller University Flow Cytometry Facility), with
smHighPurity precision. Post-sort analysis was performed to ensure the
purity of the collection process.
Analytical Assays
FACS Analysis of 1ºMG: After shaking for 5hr, microglia were collected and
washed in FACS buffer (5% FCS PBS). Cells were then blocked for 15 min
at 4ºC with 5% mouse serum. Cells were then stained for 15 minutes at 4ºC
with phycoerithryn (PE) conjugated primary antibodies: anti-CD11b (1:200)
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(BD), or its corresponding PE-conjugated isotype, anti-rat IgG2b (1:200)
(BD); anti-CD11c (1:200), or isotype anti-hamster IgG1 (1:200). Staining
for DEC205 was done with a 15-minute incubation at 4ºC with biotin
conjugated anti-DEC205 (2.8ng/µl), or its biotin conjugated isotype anti-III-
10 (2.8ng/µl) (both antibodies kindly provided by Dr. Ralph Steinman’s
laboratory), and a secondary incubation with PE-conjugated strepavidin
(1:500). Finally, cells were washed 3X in FACS buffer and then analyzed
using a BD FACSCalibur system (BD) under the FITC and PE channels.
Data was analyzed using FlowJo software (Tree Star Inc., OR).
Immunocytochemistry: Cells were seeded onto Poly-L coated glass cover-
slips in a 24-well plate (2x104 cells/well). After treatments, cells were fixed
in 4% paraformaldehyde PBS, permeabilized, and blocked in 5% goat or
horse serum PBS, 0.5% Tween (Sigma) for 1hr at R.T. Primary antibodies
incubations were done overnight at 4ºC in blocking buffer: anti-NFκB p65
(C-20, sc-372) (1:500) (Santa Cruz Biotech, Santa Cruz, CA), or anti-
phospho-p38 MAPK (Thr180/Tyr182) (1:1000) (Cell Signaling Tech,
Danvers, MA). Cells were washed 3X in 1% serum PBS, and then incubated
for 1hr at room temperature with species-specific fluorescent secondary
antibodies coupled to Alexa-594 (1:1000 Molecular Probes). Coverslips
157
were washed 5X and then mounted on glass slides using Dako fluorescent
mounting media (Dako, Carpinteria, CA) for microscopy. Confocal images
were acquired using a LSM510 confocal Zeiss Axioplan microscope with a
kripton/argon laser and a HeNe laser (Rockefeller University Bioimaging
Facility).
Cytokine and Nitric Oxide (NO) Measurements: 24hr after microglia
stimulation with LPS or LPS+INFγ, supernatants were collected, cleared of
cell debris by centrifugation at 4°C for 5 minutes at 2500 rpm (Eppendorph
microfuge), and then frozen at –20°C until further analysis. Cytokines
(TNFα and IL-6) were measured by enzyme linked immuno-absorbent assay
(ELISA) following manufacturer’s instructions (eBioscience, CA). NO was
quantified using the Greiss assay (Promega).
Western Blotting: Cultured cells were rinsed in cold PBS supplemented with
Ca2+Mg2+ and scraped in ice-cold protein lysis buffer (6M Urea, 20mM Tris-
HCl pH7.5, 2%SDS, 10% glycerol, 1% protease inhibitor cocktail (Sigma))
supplemented with phosphatase inhibitor (1µM NaVO4; Sigma). Cell
lysates were sonicated to homogeneity and then quantified using the BioRad
Dc protein assay (BioRad, Hercules, CA). Samples were stored at –20°C
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until processed by Western blot. Briefly, equal amounts of protein were
mixed with Laemli loading buffer (Invitrogen), heated at 70°C for 10min,
and separated by SDS-polyacrylamide gel electrophoresis performed under
reducing conditions with 4-12% acrylamide NuPage gels according to
manufacturer’s instructions (Invitrogen). Resolved proteins were transferred
to PDVF membranes (Invitrogen).
Membranes were rinsed in 0.1M Tris-Buffered Saline with 0.1%
Tween-20 (TBS-T) and blocked with a solution of 5% non-fat dry milk in
TBS-T for 1hr at room temperature on an orbital shaking platform.
Membranes were then washed with TBS-T and incubated overnight at 4°C
in 5% bovine serum albumin (BSA) (Sigma) in TBS-T solution with
primary antibody.
Antibodies used for microglia studies included: anti-p38MAPK
(1:2000) (Santa Cruz Biotech); anti-phospho-p38MAPK (1:2000) (Cell
Signaling); anti-IL-1β (1:2000) (Chemicon, Temecula, CA); anti-Actin
A5441 (1:40,000) (Sigma); anti-ERK1/2 MAPK 9102 (1:1000) (Cell
Signaling); anti-phosphoERK1/2 MAPK 9101(Thr202/Tyr204) (1:2000) (Cell
Signaling); anti-ERα 6F-11 (1:1000) (Novocastra); anti-ERβ  80424
(1:25,000) (Merck, Rahway, NJ); anti-GR antiserum (1:2000; M20, Santa
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Cruz Biotechnology, Santa Cruz, CA); and anti-11βHSD-1 125-11 (1:1,000;
Seckl Lab, UK).
Primary antibodies used for the EtC.1 studies included: anti-NeuN
MAB377 (1:2000) (Chemicon); anti-GFAP MAB3402 (1:2000)
(Chemicon); anti-Doublecortin SC-8067 (1:1000) (Santa Cruz Biotech);
anti-Nestin MAB353 (1:2000) (Chemicon); anti-Musashi AB5977 (1:1000)
(Chemicon); anti-Vimentin (1:250) (Hybridoma Bank, University of Iowa,
#40E-C); anti-FMRP MAB2160 (1:2000) (Chemicon); anti-CREB 9192
(1:2000) (Cell Signaling); anti-phospho CREB 9198(Ser133) (1:2000) (Cell
Signaling).
After overnight incubation in primary antibodies, membranes were
washed and incubated with horseradish peroxidase-conjugated species-
specific anti-antiserum (1:20,000) (Pierce, Rockford, IL) in blocking
solution. After washing, membranes were developed with SuperSignal West
Pico substrate (Pierce, Rockford, IL), and then exposed to X-Ray film (X-
OMAT AR; Kodak, Rochester, NY). To control for protein loading,
membranes were incubated in Restore Western Blot Stripping Buffer
(Pierce), washed, and immunoblotted as described above using an anti-Actin
antibody. Developed films were analyzed by densitometry using a
computerized image analysis software (MCID-M4; Imaging Research, Inc,
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St. Catherines, ON), and the data was normalized as follows: protein band
(density*area)/actin (density*area). For phospho-proteins, their
corresponding non-phosphorylated forms were for normalization.
Real-time PCR: Adult microglia were sorted by FACS into RNA lysis buffer
(Absolute RNA Microprep kit (Stratagene, La Jolla, CA)), frozen in dry ice,
and kept at -80ºC until processing. RNA was isolated using the Absolute
RNA Microprep kit.
RNA from 1°MG cultures was obtained by rinsing the cell cultures
with PBS and then lysing cells in 350µl RNA lysis buffer (RNeasy Mini kit
(Quiagen, Valencia, CA)). RNA was extracted using the RNeasy Mini kit
protocol (Qiagen). Both extraction methods included a step with DNAse
incubation (Qiagen) to remove residual DNA.
RNA quality and concentration were then assessed by measurement of
optical density at 260 and 280 nm (1°MG) or RNA was quantified with
RiboGreen RNA Quantitation kit (Molecular Probes) following
manufacturer instructions (ex vivo MG). 10ng of RNA were retrotranscribed
with SuperScript II Reverse Transcriptase (Invitrogen) and 3µl of a 1:3
dilution of the cDNA were amplified by real-time PCR using SYBR Green
master mix (AB) in a 7900HT SDS thermal cycler (AB). The gene
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transcripts quantified were 11β hydroxysteroid dehydrogenase type 1 and
type 2 (11βHSD-1, -2), peripheral benzodiazepine receptor (PBR),
steroidogenic acute regulatory protein (StAR), cytochrome p450 side chain
cleavage enzyme (p450scc), cytochrome p450 21-hydroxylase (p450c21),
cytochrome p450 17-hydroxylase (p450c17), aryl sulfatase (Arsa), steroid
sulfatase (StS), DHEA sulfotransferase (Sulft), 3β  hydroxysteroid
dehydrogenase type 1,2,4,7 (3βHSD-1, -2, -4, -7), 17β hydroxysteroid
dehydrogenase (17βHSD-1), cytochrome p450 aromatase (p450Arom),
steroid 5α reductase (5αR), 3α hydroxysteroid dehydrogenase (3αHSD),
and ribosomal protein L27A (L27A). Primers sequences were designed
using Primer Express Software (ABI) and are indicated in Table 1;
amplicons were designed to span two exons in order to avoid potential
contaminating DNA amplification. All primers were blasted on NCBI
databases for target specificity and tested using appropriate positive control
tissues such as ovary and adrenal glands. All samples were tested in
triplicate in order to eliminate pipetting errors and the average Ct (threshold
cycle) was used to calculate the relative amount of product by the -ΔΔCt-
method (AB), using the ribosomal L27A as a housekeeping gene. The ratio
of enzyme Ct to L27A Ct values was calculated as a way of assessing the
relative expression levels of each enzyme comparing 1°MG and ex vivo MG.
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In each experiment, both positive (1µg ovary mRNA/cDNA 1:3) and
negative (RT minus and water) controls were included to ensure that the
PCR reaction was working properly.
Thin Layer Chromatography (TLC) Identification of Glucocorticoids:
Products from H3-11-dehydro-corticosterone (11-DH-Cort) and H3-
corticosterone (Cort) incubations were separated by TLC on aluminum
sheets pre-coated with silica gel containing a fluorescent indicator (Fisher).
Re-constituted samples and non-radioactive steroids were spotted on TLC
sheets and separated using chloroform/ethyl-acetate (60/40 % by vol.).
Unlabeled steroids were purchased from Sigma. After steroid separation, 11-
DH-Cort and Cort were visualized under UV light and pencil-marked. TLC
plates were then scanned using a BioScan H3 scanner (BioScan, Washington,
DC). Radioactivity peaks were analyzed using WinScan software (BioScan).
In parallel, quantification was also conducted by cutting the TLC aluminum
sheet where 11-DH-Cort and Cort spots were located, and measuring
radioactivity by scintillation counting. Data are presented as % radioactivity
of initial substrate.
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TLC Identification of Steroid hormone Metabolites: Products of tritiated
steroid incubations were separated by TLC on silica gel containing a
fluorescent indicator on pre-coated aluminum sheets (Fisher, Carlsbad, CA)
using chloroform/ethyl-acetate/xylene (68/23/9 % by vol. for [3H] DHEA)
and (62/21/17 % by vol. for [3H] AD). Non-radioactive steroids of known
identity were added to the TLC sheets on lanes adjacent to the putative
metabolites and were visualized and identified by their chromogenic
properties after spraying with 5% (by vol.) sulphuric acid in methanol and
heating on a hot plate. Unlabeled steroids used were 17β-estradiol (E2) and
estrone (E1) (Sigma); and testosterone (T), androstenedione (AD), 5α-
androstenedione (5αAD), dehydroepiandrosterone (DHEA), 5-
androstenediol (Adiol), and dehydro-testosterone (DHT) (Steraloids Inc,
New Port, RI). Purity of [3H]-DHEA and [3H]-AD (<98 %) was determined
by TLC.
Immunofluorescence: 24hr, 48hr or 5 days after I.P. injection of LPS, mice
were transcardially perfused with PBS, followed by 4% paraformaldehyde
(PFA). Fixed brains were extracted, post-fixed overnight at 4°C in 4%PFA,
and then stored at –20°C in cryoprotectant (sucrose %). Coronal sections
(30M) were obtained using a Leica vibratome (Leica, ). Sections were rinsed
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in PBS and then washed 3x in TBS-Triton 1% (TBS-Tr), blocked in 3% goat
serum for 1hr at room temperature, and then incubated overnight at 4°C in
primary antibody dilutions in 3% BSA TBS-Tr: 11βHSD-1 (1:500); GFAP
(1:1000); NeuN (1:1000). The following day, sections were washed 5x in
TBS-Tr and then incubated for 1hr at room temperature with the appropriate
Rhodamine-Red-X conjugated species-specific secondary antibodies.
Sections were washed 5x in TBS-Tr and then rinsed in 0.1M PB before
mounting on glass slides and cover-slipping with Dako aqueous fluorescent
mounting media (Dako). Mounted sections were visualized by confocal
microscopy using a Zeiss LSM confocal microscope. Z-stack image
reconstructions and co-localization analysis were done using LSM software
(Rockefeller University Bioimaging Facility) and images were labeled and
marked in Adobe Photoshop (Adobe, San Jose, CA).
EtC.1 Transfection and Luciferase Assay: EtC.1 cells were seeded in 24-well
plates, 2x104 cells/well, in DMEM containing 10% charcoal stripped serum.
24hr later cells were transfected using Lipofectamine Plus (Invitrogen),
following manufacturer’s instructions, with 0.4µg of plasmid DNA/well.
The 3X ERE-Luciferase plasmid was a generous gift of Don McDonnell
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(Duke University Durham, NC), and the β-Galactosidase plasmid was from
Promega (pSV-β-Gal control vector). 24hr after transfection, cells were
incubated with various concentrations of E2 or Adiol for another 24hr. ICI
pre-treatment was done for 30 minutes. Cell lysates were prepared and
luciferase activity measured using Promega Luciferase Assay System
according to manufacturer’s instructions (Promega). β-Gal activity was
measured from cell lysates to normalize for transfection efficiency.
Statistics:  Statistical analysis was performed using StatView (SAS Institute
Inc., Cary, NC). Experiments involving 2 groups were compared using a
Student t-test. Experiments involving more than 2 groups were compared by
Analysis of Variance (ANOVA), followed by posthoc analysis with Tukey-
Kramer Honestly Significant Difference (HSD) when variances were
homogeneous (using Equality of Variance F test); or with non-parametric
Games-Howell test. Graphs show the mean ± the standard error of the mean
(S.E.M.). P<0.05 was considered statistically significant. *, p<0.05, **,
p<0.01 and ***, p<0.0001; (n.s.), non-significant.
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